BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-832. [PMID: 9121257 DOI: 10.1016/s0140-6736(96)07642-8] [Cited by in Crossref: 2115] [Cited by in F6Publishing: 578] [Article Influence: 84.6] [Reference Citation Analysis]
Number Citing Articles
1 Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18. [PMID: 15690074 DOI: 10.1172/JCI24282] [Reference Citation Analysis]
2 Elemeery MN, Badr AN, Mohamed MA, Ghareeb DA. Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients. World J Gastroenterol 2017; 23(21): 3864-3875 [PMID: 28638226 DOI: 10.3748/wjg.v23.i21.3864] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
3 Wiegand SB, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Böker KH, Grigorian N, Link R, Naumann U, John C, Lueth S, Malfertheiner P, Manns MP, Wedemeyer H, Sarrazin C, Cornberg M. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. PLoS One 2015;10:e0145622. [PMID: 26699619 DOI: 10.1371/journal.pone.0145622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Deng Y, Palmeri ML, Rouze NC, Rosenzweig SJ, Abdelmalek MF, Nightingale KR. Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver. Ultrasound Med Biol 2015;41:1948-57. [PMID: 25896024 DOI: 10.1016/j.ultrasmedbio.2015.02.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
5 Booth JC, O'Grady J, Neuberger J;  Thr Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut. 2001;49 Suppl 1:I1-21. [PMID: 11413125 DOI: 10.1136/gut.49.suppl_1.i1] [Cited by in Crossref: 86] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
6 González-Moreno J, Payeras-Cifre A. Hepatitis C virus infection: looking for interferon free regimens. ScientificWorldJournal. 2013;2013:825375. [PMID: 23710151 DOI: 10.1155/2013/825375] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 2001;21:266-271. [PMID: 11454190 DOI: 10.1034/j.1600-0676.2001.021004266.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 101] [Article Influence: 5.0] [Reference Citation Analysis]
8 Lee HS, Kim JK, Cheong JY, Han EJ, An SY, Song JH, Jung YJ, Jeon SC, Jung MW, Jang EJ. Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis. Korean J Hepatol. 2010;16:369-375. [PMID: 21415580 DOI: 10.3350/kjhep.2010.16.4.369] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
9 Ishida JH, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, Terrault NA. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol. 2008;6:69-75. [PMID: 18166478 DOI: 10.1016/j.cgh.2007.10.021] [Cited by in Crossref: 100] [Cited by in F6Publishing: 78] [Article Influence: 7.1] [Reference Citation Analysis]
10 Nishimura N, De Battista D, McGivern DR, Engle RE, Tice A, Fares-Gusmao R, Kabat J, Pomerenke A, Nguyen H, Sato S, Bock KW, Moore IN, Kleiner DE, Zamboni F, Alter HJ, Govindarajan S, Farci P. Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proc Natl Acad Sci U S A 2021;118:e2019633118. [PMID: 33888584 DOI: 10.1073/pnas.2019633118] [Reference Citation Analysis]
11 Chien SC, Chang WC, Lin PH, Chang WP, Hsu SC, Chang JC, Wu YC, Pei JK, Lin CH. A Chinese herbal medicine, jia-wei-xiao-yao-san, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. ScientificWorldJournal 2014;2014:217525. [PMID: 24995353 DOI: 10.1155/2014/217525] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
12 Marchesini G, Bianchi G, Fabbri A. LONG-TERM MANAGEMENT OF ALCOHOLIC LIVER DISEASE. Clinics in Liver Disease 1998;2:821-38. [DOI: 10.1016/s1089-3261(05)70044-1] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Schackman BR. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One 2014;9:e97317. [PMID: 24842841 DOI: 10.1371/journal.pone.0097317] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 9.6] [Reference Citation Analysis]
14 Sawamoto R, Nagano J, Kajiwara E, Sonoda J, Hiramoto T, Sudo N. Inhibition of emotional needs and emotional wellbeing predict disease progression of chronic hepatitis C patients: an 8-year prospective study. Biopsychosoc Med 2016;10:24. [PMID: 27478498 DOI: 10.1186/s13030-016-0075-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Elhosary YA, Saleh SM, Ezzat WM, Clevert DA. Diagnostic Accuracy of Acoustic Radiation Force Impulse (ARFI) in Diagnosis of Liver Fibrosis among Egyptian Patients with Chronic HCV Infection. Open Access Maced J Med Sci 2016;4:374-80. [PMID: 27703558 DOI: 10.3889/oamjms.2016.064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Miller-Dickson MD, Meszaros VA, Almagro-Moreno S, Brandon Ogbunugafor C. Hepatitis C virus modelled as an indirectly transmitted infection highlights the centrality of injection drug equipment in disease dynamics. J R Soc Interface 2019;16:20190334. [PMID: 31480919 DOI: 10.1098/rsif.2019.0334] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-132. [PMID: 27924080 DOI: 10.1038/nrgastro.2016.176] [Cited by in Crossref: 196] [Cited by in F6Publishing: 191] [Article Influence: 32.7] [Reference Citation Analysis]
18 Werling K, Schaff Z, Dinya E, Tulassay Z. Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary. Pathol Oncol Res 2010;16:149-57. [PMID: 19757200 DOI: 10.1007/s12253-009-9195-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
19 Tesfa E, Siefu D, Belayneh Y, Mekonnen Z. Liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital: a comparative cross-sectional study, Northeast Ethiopia. BMC Res Notes 2019;12:714. [PMID: 31666123 DOI: 10.1186/s13104-019-4748-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 2011;4:391-417. [PMID: 22043231 DOI: 10.1177/1756283x11413002] [Cited by in Crossref: 141] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
21 Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 2005;43:186-91. [PMID: 15634970 DOI: 10.1128/JCM.43.1.186-191.2005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
22 Chen J, King K, Zhang JX. Effect of caloric restriction on hepatic sinusoidal system and stellate cells in mice. J Aging Res. 2014;2014:670890. [PMID: 24649364 DOI: 10.1155/2014/670890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
23 Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat. 2015;22:376-383. [PMID: 25219291 DOI: 10.1111/jvh.12311] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
24 Bailey H, Nizova N, Martsynovska V, Volokha A, Malyuta R, Cortina-Borja M, Thorne C; Ukraine European Collaborative Study in EuroCoord. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study. BMC Infect Dis 2016;16:755. [PMID: 27955711 DOI: 10.1186/s12879-016-2089-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Nunes D, Saitz R, Libman H, Cheng DM, Vidaver J, Samet JH. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res. 2006;30:1520-1526. [PMID: 16930214 DOI: 10.1111/j.1530-0277.2006.00183.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
26 Teama SH, Agwa SH, El Sayed OA, Sayed MM, Abd El Samee A, El Nakeep S. Assessment of interleukin-28B (interferon λ3) rs12979860 C/T gene polymorphism and the risk for hepatocellular carcinoma in chronic hepatitis C cirrhotic patients: . Egyptian Liver Journal 2016;6:48-53. [DOI: 10.1097/01.elx.0000515930.52529.6c] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52. [PMID: 16614742 DOI: 10.7150/ijms.3.47] [Cited by in Crossref: 454] [Cited by in F6Publishing: 431] [Article Influence: 28.4] [Reference Citation Analysis]
28 Peña-Asensio J, Sanz-de-Villalobos E, Miquel J, Larrubia JR. Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history. World J Hepatol 2020; 12(10): 754-765 [PMID: 33200014 DOI: 10.4254/wjh.v12.i10.754] [Reference Citation Analysis]
29 George M, Paci P, Taner T. Significance of progressive liver fibrosis in pediatric liver transplants: A review of current evidence. World J Gastroenterol 2020; 26(17): 1987-1992 [PMID: 32536769 DOI: 10.3748/wjg.v26.i17.1987] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Sagnelli C, Uberti-Foppa C, Pasquale G, De Pascalis S, Coppola N, Albarello L, Doglioni C, Lazzarin A, Sagnelli E. Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection. Infection. 2013;41:959-967. [PMID: 23839212 DOI: 10.1007/s15010-013-0502-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
31 Attallah AM, Abdallah SO, Albannan MS, Omran MM, Attallah AA, Farid K. Impact of Hepatitis C Virus/Schistosoma mansoni Coinfection on the Circulating Levels of HCV-NS4 Protein and Extracellular-Matrix Deposition in Patients with Different Hepatic Fibrosis Stages. Am J Trop Med Hyg 2016;95:1044-50. [PMID: 27527625 DOI: 10.4269/ajtmh.16-0129] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Poynard T, Deckmyn O, Munteanu M, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V; FIBROFRANCE Group. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. BMJ Open 2015;5:e010017. [PMID: 26700292 DOI: 10.1136/bmjopen-2015-010017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
33 Enomoto M, Ikura Y, Tamori A, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Murakami Y, Kawada N. Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. United European Gastroenterol J 2018;6:1391-400. [PMID: 30386612 DOI: 10.1177/2050640618791053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
34 Day CP. Heavy drinking greatly increases the risk of cirrhosis in patients with HCV hepatitis. Gut 2001;49:750-1. [PMID: 11709504 DOI: 10.1136/gut.49.6.750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Kagawa T, Keeffe EB. Long-term effects of antiviral therapy in patients with chronic hepatitis C. Hepat Res Treat 2010;2010:562578. [PMID: 21188198 DOI: 10.1155/2010/562578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
36 Scognamiglio P, Galati V, Navarra A, Longo MA, Aloisi MS, Antonini MG, Puoti M, Almasio PL, Ippolito G, Girardi E. Impact of hepatitis C virus infection on lifestyle. World J Gastroenterol 2007; 13(19): 2722-2726 [PMID: 17569142 DOI: 10.3748/wjg.v13.i19.2722] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
37 Persson EC, Schwartz LM, Park Y, Trabert B, Hollenbeck AR, Graubard BI, Freedman ND, McGlynn KA. Alcohol consumption, folate intake, hepatocellular carcinoma, and liver disease mortality. Cancer Epidemiol Biomarkers Prev 2013;22:415-21. [PMID: 23307533 DOI: 10.1158/1055-9965.EPI-12-1169] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
38 Fuster D, Tsui JI, Cheng DM, Quinn EK, Bridden C, Nunes D, Libman H, Saitz R, Samet JH. Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection. Alcohol Clin Exp Res. 2013;37:1527-1535. [PMID: 23647488 DOI: 10.1111/acer.12129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
39 Fried MW, Kroner BL, Preiss LR, Wilhelmsen K, Goedert JJ; Multicenter Hemophilia Cohort Study. Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance. Gastroenterology 2006;131:757-64. [PMID: 16952545 DOI: 10.1053/j.gastro.2006.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
40 Michalczuk MT, Kappel CR, Birkhan O, Bragança AC, Alvares-da-Silva MR. HOMA-AD in Assessing Insulin Resistance in Lean Noncirrhotic HCV Outpatients. Int J Hepatol 2012;2012:576584. [PMID: 22848841 DOI: 10.1155/2012/576584] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
41 Heathcote J, Ramji A. When to treat patients with chronic hepatitis C. Curr Gastroenterol Rep 2004;6:261-3. [PMID: 15245691 DOI: 10.1007/s11894-004-0074-6] [Reference Citation Analysis]
42 Huang CF, Huang JF, Chen WC, Yeh ML, Huang CI, Yang JF, Chuang WL, Dai CY, Hsieh MY, Lin ZY, Chen SC, Yu ML. The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. Hepatol Int 2013;7:180-7. [PMID: 26201632 DOI: 10.1007/s12072-012-9394-z] [Reference Citation Analysis]
43 Halász T, Horváth G, Kiss A, Pár G, Szombati A, Gelley F, Nemes B, Kenessey I, Piurkó V, Schaff Z. Evaluation of Histological and non-Invasive Methods for the Detection of Liver Fibrosis: The Values of Histological and Digital Morphometric Analysis, Liver Stiffness Measurement and APRI Score. Pathol Oncol Res 2016;22:1-6. [PMID: 26189126 DOI: 10.1007/s12253-015-9964-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
44 Lake-Bakaar G, Ruffini L, Kuzmic P. Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon. Dig Dis Sci 2003;48:126-39. [PMID: 12645800 DOI: 10.1023/a:1021798701772] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Pan YF, Zheng Y, Qin T, Feng L, Zhang Q, Ping XG, Pan YT, Wang XP, Bai L, Li HH. Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion. Exp Ther Med. 2016;12:3476-3484. [PMID: 27882182 DOI: 10.3892/etm.2016.3792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Grubyte S, Urboniene J, Nedzinskiene L, Jelinskaite A, Zagminas K, Ambrozaitis A, Jancoriene L. Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study. PLoS One 2021;16:e0246704. [PMID: 33606700 DOI: 10.1371/journal.pone.0246704] [Reference Citation Analysis]
47 Nishikawa H, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y. The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes 2012;5:135. [PMID: 22405406 DOI: 10.1186/1756-0500-5-135] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
48 Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, Hill A, Apple R, Cheng S, Thomas H. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut. 2003;52:1206-1210. [PMID: 12865283 DOI: 10.1136/gut.52.8.1206] [Cited by in Crossref: 99] [Cited by in F6Publishing: 100] [Article Influence: 5.2] [Reference Citation Analysis]
49 Ganesan M, Zhang J, Bronich T, Poluektova LI, Donohue TM, Tuma DJ, Kharbanda KK, Osna NA. Acetaldehyde accelerates HCV-induced impairment of innate immunity by suppressing methylation reactions in liver cells. Am J Physiol Gastrointest Liver Physiol. 2015;309:G566-G577. [PMID: 26251470 DOI: 10.1152/ajpgi.00183.2015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
50 Singal AK, Salameh H, Singal A, Jampana SC, Freeman DH, Anderson KE, Brunder D. Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. World J Gastrointest Pharmacol Ther 2013; 4(2): 16-22 [PMID: 23667769 DOI: 10.4292/wjgpt.v4.i2.16] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
51 Wang Y, Hou JL. Current strategies for quantitating fibrosis in liver biopsy. Chin Med J (Engl) 2015;128:252-8. [PMID: 25591571 DOI: 10.4103/0366-6999.149223] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
52 Lee DH, Lee ES, Lee JY, Bae JS, Kim H, Lee KB, Yu SJ, Cho EJ, Lee JH, Cho YY, Han JK, Choi BI. Two-Dimensional-Shear Wave Elastography with a Propagation Map: Prospective Evaluation of Liver Fibrosis Using Histopathology as the Reference Standard. Korean J Radiol 2020;21:1317-25. [PMID: 32729274 DOI: 10.3348/kjr.2019.0978] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Ogawa M, Matsuoka S, Karp SJ, Moriyama M. Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives. Int J Mol Sci 2020;21:E4906. [PMID: 32664553 DOI: 10.3390/ijms21144906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Wu T, Konyn PG, Cattaneo AW, Saab S. New Face of Hepatitis C. Dig Dis Sci 2019;64:1782-8. [PMID: 30756208 DOI: 10.1007/s10620-019-05511-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
55 Proeschold-Bell RJ, Evon DM, Makarushka C, Wong JB, Datta SK, Yao J, Patkar AA, Mannelli P, Hodge T, Naggie S, Wilder JM, Fried MW, Niedzwiecki D, Muir AJ. The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. Contemp Clin Trials 2018;72:73-85. [PMID: 30006024 DOI: 10.1016/j.cct.2018.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
56 Zhang Y, Jin N, Deng J, Guo Y, White SB, Yang GY, Omary RA, Larson AC. Intra-voxel incoherent motion MRI in rodent model of diethylnitrosamine-induced liver fibrosis. Magn Reson Imaging 2013;31:1017-21. [PMID: 23598061 DOI: 10.1016/j.mri.2013.03.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
57 Fujiwara A, Sakaguchi K, Fujioka S, Iwasaki Y, Senoh T, Nishimura M, Terao M, Shiratori Y. Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels. J Gastroenterol 2008;43:484-91. [PMID: 18600393 DOI: 10.1007/s00535-008-2183-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
58 Bacchetti P, Boylan RD, Terrault NA, Monto A, Berenguer M. Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant. Int J Biostat 2010;6:Article 7. [PMID: 20305705 DOI: 10.2202/1557-4679.1213] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
59 Burza MA, Motta BM, Mancina RM, Pingitore P, Pirazzi C, Lepore SM, Spagnuolo R, Doldo P, Russo C, Lazzaro V. DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology. 2016;63:418-427. [PMID: 26517016 DOI: 10.1002/hep.28322] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
60 Peltekian KM, Bain VG, Lee SS, Sherman M, Cooper CL, Yoshida EM, Marotta PJ, Krajden M, Balshaw R, Deschênes M. Is pre-treatment liver biopsy necessary for all hepatitis C genotypes? Annals of Hepatology 2011;10:260-9. [DOI: 10.1016/s1665-2681(19)31537-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, Esmat G, Hamid MA, Mohamed MK, Fontanet A. Higher clearance of hepatitis C virus infection in females compared with males. Gut 2006;55:1183-7. [PMID: 16434426 DOI: 10.1136/gut.2005.078147] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 4.8] [Reference Citation Analysis]
62 Isgro G, Calvaruso V, Andreana L, Luong TV, Garcovich M, Manousou P, Alibrandi A, Maimone S, Marelli L, Davies N. The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis. J Gastroenterol. 2013;48:921-929. [PMID: 23124603 DOI: 10.1007/s00535-012-0694-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
63 Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002;36:S220-5. [PMID: 12407597 DOI: 10.1053/jhep.2002.36811] [Cited by in Crossref: 14] [Cited by in F6Publishing: 63] [Article Influence: 0.7] [Reference Citation Analysis]
64 Juzėnas S, Kupčinskas J, Valantienė I, Šumskienė J, Petrenkienė V, Kondrackienė J, Kučinskas L, Kiudelis G, Skiecevičienė J, Kupčinskas L. Association of HFE gene C282Y and H63D mutations with liver cirrhosis in the Lithuanian population. Medicina (Kaunas) 2016;52:269-75. [PMID: 27816425 DOI: 10.1016/j.medici.2016.09.004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
65 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300-4308. [PMID: 18666317 DOI: 10.3748/wjg.v14.i27.4300] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Solomon SS, Srikrishnan AK, McFall AM, Kumar MS, Saravanan S, Balakrishnan P, Solomon S, Thomas DL, Sulkowski MS, Mehta SH. Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India. PLoS One 2016;11:e0147879. [PMID: 26812065 DOI: 10.1371/journal.pone.0147879] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
67 Tao Y, Wang N, Qiu T, Sun X. The Role of Autophagy and NLRP3 Inflammasome in Liver Fibrosis. Biomed Res Int 2020;2020:7269150. [PMID: 32733951 DOI: 10.1155/2020/7269150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
68 Mohsen AH; Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;48:707-13. [PMID: 11302973 DOI: 10.1136/gut.48.5.707] [Cited by in Crossref: 69] [Cited by in F6Publishing: 80] [Article Influence: 3.3] [Reference Citation Analysis]
69 Li H, McMahon BJ, McArdle S, Bruden D, Sullivan DG, Shelton D, Deubner H, Gretch DR. Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology 2008;375:580-91. [PMID: 18343477 DOI: 10.1016/j.virol.2008.02.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
70 McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol. 2000;15:945-951. [PMID: 11022838 DOI: 10.1046/j.1440-1746.2000.02233.x] [Cited by in Crossref: 160] [Cited by in F6Publishing: 149] [Article Influence: 7.6] [Reference Citation Analysis]
71 Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, Sugimoto K, Murata K, Nakano T. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005; 11(4): 476-481 [PMID: 15641129 DOI: 10.3748/wjg.v11.i4.476] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 98] [Article Influence: 5.9] [Reference Citation Analysis]
72 Varma V, Webb K, Mirza DF. Liver transplantation for alcoholic liver disease. World J Gastroenterol 2010;16:4377-93. [PMID: 20845504 DOI: 10.3748/wjg.v16.i35.4377] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chen JJ, Yu ML. Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. Sci Rep 2018;8:15058. [PMID: 30305682 DOI: 10.1038/s41598-018-33448-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
74 Wan SZ, Liu C, Huang CK, Luo FY, Zhu X. Ursolic Acid Improves Intestinal Damage and Bacterial Dysbiosis in Liver Fibrosis Mice. Front Pharmacol 2019;10:1321. [PMID: 31736766 DOI: 10.3389/fphar.2019.01321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
75 Wan S, Nie Y, Zhang Y, Huang C, Zhu X. Gut Microbial Dysbiosis Is Associated With Profibrotic Factors in Liver Fibrosis Mice. Front Cell Infect Microbiol 2020;10:18. [PMID: 32083022 DOI: 10.3389/fcimb.2020.00018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
76 Jeong WI, Gao B. Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol. 2008;23 Suppl 1:S112-S118. [PMID: 18336653 DOI: 10.1111/j.1440-1746.2007.05274.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
77 Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002;50:253-8. [PMID: 11788569 DOI: 10.1136/gut.50.2.253] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
78 Castro R, Perazzo H, Grinsztejn B, Veloso VG, Hyde C. Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. Int J Hepatol. 2015;2015:852968. [PMID: 26693356 DOI: 10.1155/2015/852968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
79 Chou CT, Chen RC, Lee CW, Ko CJ, Wu HK, Chen YL. Prediction of microvascular invasion of hepatocellular carcinoma by pre-operative CT imaging. Br J Radiol 2012;85:778-83. [PMID: 21828149 DOI: 10.1259/bjr/65897774] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
80 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
81 Wise M, Finelli L, Sorvillo F. Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data. Public Health Rep 2010;125:414-22. [PMID: 20433036 DOI: 10.1177/003335491012500310] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
82 Inoue H, Shimizu I, Lu G, Itonaga M, Cui X, Okamura Y, Shono M, Honda H, Inoue S, Muramatsu M. Idoxifene and estradiol enhance antiapoptotic activity through estrogen receptor-beta in cultured rat hepatocytes. Dig Dis Sci. 2003;48:570-580. [PMID: 12757172 DOI: 10.1023/a:1022553119715] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
83 Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20(10): 2515-2532 [PMID: 24627588 DOI: 10.3748/wjg.v20.i10.2515] [Cited by in CrossRef: 190] [Cited by in F6Publishing: 176] [Article Influence: 23.8] [Reference Citation Analysis]
84 Besheer T, Arafa M, El-Maksoud MA, Elalfy H, Hasson A, Zalata K, Elkashef W, Elshahawy H, Raafat D, Elemshaty W, Elsayed E, Zaghloul H, Razek AA, El-Bendary M. Diagnosis of cirrhosis in patients with chronic hepatitis C genotype 4: Role of ABCB11 genotype polymorphism and plasma bile acid levels. Turk J Gastroenterol 2018;29:299-307. [PMID: 29755014 DOI: 10.5152/tjg.2018.17570] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
85 Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001;323:1151-5. [PMID: 11711405 DOI: 10.1136/bmj.323.7322.1151] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 3.2] [Reference Citation Analysis]
86 Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164-2170. [PMID: 23280550 DOI: 10.1002/hep.26218] [Cited by in Crossref: 307] [Cited by in F6Publishing: 293] [Article Influence: 34.1] [Reference Citation Analysis]
87 Hagström H, Hemmingsson T, Discacciati A, Andreasson A. Risk Behaviors Associated with Alcohol Consumption Predict Future Severe Liver Disease. Dig Dis Sci 2019;64:2014-23. [PMID: 30761471 DOI: 10.1007/s10620-019-05509-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
88 El-Mesallamy HO, Hamdy NM, Rizk HH, El-Zayadi AR. Apelin serum level in Egyptian patients with chronic hepatitis C. Mediators Inflamm 2011;2011:703031. [PMID: 22007137 DOI: 10.1155/2011/703031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
89 Osna NA, Ganesan M, Kharbanda KK. Hepatitis C, innate immunity and alcohol: friends or foes? Biomolecules 2015;5:76-94. [PMID: 25664450 DOI: 10.3390/biom5010076] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
90 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 128] [Article Influence: 11.4] [Reference Citation Analysis]
91 Nicoară-Farcău O, Rusu I, Stefănescu H, Tanțău M, Badea RI, Procopeț B. Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease. World J Gastroenterol 2020; 26(22): 3000-3011 [PMID: 32587444 DOI: 10.3748/wjg.v26.i22.3000] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
92 Orita N, Shimakami T, Sunagozaka H, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Takatori H, Kawaguchi K, Kitamura K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. Clin J Gastroenterol 2019;12:63-70. [PMID: 29995231 DOI: 10.1007/s12328-018-0884-y] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
93 Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL; HALT-C Trial Group. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010;138:136-46. [PMID: 19766643 DOI: 10.1053/j.gastro.2009.09.007] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
94 Burra P, Lucey MR. Liver transplantation for alcoholic liver disease. Clin Liver Dis (Hoboken) 2013;2:92-5. [PMID: 30992833 DOI: 10.1002/cld.204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
95 Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12 Suppl 2:S2. [PMID: 23173556 DOI: 10.1186/1471-2334-12-s2-s2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
96 White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012;55:759-768. [PMID: 21858849 DOI: 10.1002/hep.24618] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
97 El-Zayadi A, Selim O, Hamdy H, El-Tawil A, Badran HM, Attia M, Saeed A. Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients. World J Gastroenterol 2004; 10(20): 2963-2966 [PMID: 15378774 DOI: 10.3748/wjg.v10.i20.2963] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
98 Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One 2017;12:e0168713. [PMID: 28056030 DOI: 10.1371/journal.pone.0168713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
99 Ishii K, Takamura N, Shinohara E, Shin HY, Ikehara T, Hata S, Kawafune T, Sumino Y, Ohmoto Y. Intracellular cytokine analysis of CD4-positive T cells predictive of sustained response to interferon therapy for patients with chronic hepatitis C. Dig Dis Sci 2002;47:778-83. [PMID: 11991609 DOI: 10.1023/a:1014740000412] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
100 Guzmán Aroca F, Ayala I, Serrano L, Berná-Serna JD, Castell MT, García-Pérez B, Reus M. Assessment of liver steatosis in chicken by using acoustic radiation force impulse imaging: preliminary results. Eur Radiol 2010;20:2367-71. [PMID: 20445981 DOI: 10.1007/s00330-010-1808-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
101 Dhyani M, Anvari A, Samir AE. Ultrasound elastography: liver. Abdom Imaging 2015;40:698-708. [PMID: 25690689 DOI: 10.1007/s00261-015-0373-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
102 Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. PLoS One 2013;8:e58380. [PMID: 23505497 DOI: 10.1371/journal.pone.0058380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Araújo RC, Dias FC, Bertol BC, Silva DM, Almeida PH, Teixeira AC, Souza FF, Villanova MG, Ramalho LNZ, Donadi EA, Martinelli ALC. Liver HLA-E Expression Is Associated with Severity of Liver Disease in Chronic Hepatitis C. J Immunol Res 2018;2018:2563563. [PMID: 29951556 DOI: 10.1155/2018/2563563] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
104 Bessa SS, Mohamed Ali EM, Abd El-Wahab Ael-S, Nor El-Din SA. Heme oxygenase-1 mRNA expression in egyptian patients with chronic liver disease. Hepat Mon 2012;12:278-85. [PMID: 22690236 DOI: 10.5812/hepatmon.846] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
105 Germani G, Tsochatzis E, Papastergiou V, Burroughs AK. HCV in liver transplantation. Semin Immunopathol. 2013;35:101-110. [PMID: 22829333 DOI: 10.1007/s00281-012-0329-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
106 Szekerczés T, Gógl A, Illyés I, Mandl J, Borka K, Kiss A, Schaff Z, Lendvai G, Werling K. Autophagy, Mitophagy and MicroRNA Expression in Chronic Hepatitis C and Autoimmune Hepatitis. Pathol Oncol Res 2020;26:2143-51. [PMID: 32124227 DOI: 10.1007/s12253-020-00799-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
107 Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19(18): 2793-2798 [PMID: 23687416 DOI: 10.3748/wjg.v19.i18.2793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
108 Moura AS, Carmo RA, Teixeira AL, Leite VH, Rocha MO. Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis. 2010;29:1153-1161. [PMID: 20559676 DOI: 10.1007/s10096-010-0981-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
109 Rossi M, Mennini G, Lai Q, Ginanni Corradini S, Drudi FM, Pugliese F, Berloco PB. Liver transplantation(). J Ultrasound 2007;10:28-45. [PMID: 23396075 DOI: 10.1016/j.jus.2007.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
110 Kim J, Haacker M, Keshavjee S, Atun R. Cost-effectiveness of scaling up of hepatitis C screening and treatment: a modelling study in South Korea. BMJ Glob Health 2019;4:e001441. [PMID: 31263587 DOI: 10.1136/bmjgh-2019-001441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
111 Tillmann HL. Hepatitis C virus infection and the brain. Metab Brain Dis. 2004;19:351-356. [PMID: 15554427 DOI: 10.1023/b: mebr.0000043981.89134.39] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Kichatova VS, Kyuregyan KK, Soboleva NV, Karlsen AA, Isaeva OV, Isaguliants MG, Mikhailov MI. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. J Immunol Res 2018;2018:7685371. [PMID: 29577052 DOI: 10.1155/2018/7685371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
113 Liu JP, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection. Cochrane Database Syst Rev 2001;:CD003183. [PMID: 11687177 DOI: 10.1002/14651858.CD003183] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
114 Gobran ST, Ancuta P, Shoukry NH. A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. Front Immunol 2021;12:726419. [PMID: 34456931 DOI: 10.3389/fimmu.2021.726419] [Reference Citation Analysis]
115 McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl Infect Dis. 2000;2:166-185. [PMID: 11429029 DOI: 10.1034/j.1399-3062.2000.020403.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
116 Sanna A, Le Strat Y, Roudot-Thoraval F, Deuffic Burban S, Carrieri P, Delarocque-Astagneau E, Larsen C. Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014. Euro Surveill 2017;22:30582. [PMID: 28797326 DOI: 10.2807/1560-7917.ES.2017.22.30.30582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
117 Sheen V, Nguyen H, Jimenez M, Agopian V, Vangala S, Elashoff D, Saab S. Routine Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C: A 10 Year Experience. J Clin Transl Hepatol 2016;4:20-5. [PMID: 27047768 DOI: 10.14218/JCTH.2015.00034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Karanjia RN, Crossey MME, Cox IJ, Fye HKS, Njie R, Goldin RD, Taylor-Robinson SD. Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol 2016; 22(45): 9880-9897 [PMID: 28018096 DOI: 10.3748/wjg.v22.i45.9880] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
119 Rollet-Kurhajec KC, Moodie EE, Walmsley S, Cooper C, Pick N, Klein MB; Canadian Co-infection Cohort Study (CTN 222). Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index. PLoS One 2015;10:e0129868. [PMID: 26090666 DOI: 10.1371/journal.pone.0129868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
120 Liu QH, Li DG, Huang X, Zong CH, Xu QF, Lu HM. Suppressive effects of 17β-estradiol on hepatic fibrosis in CCl4-induced rat model. World J Gastroenterol 2004; 10(9): 1315-1320 [PMID: 15112349 DOI: 10.3748/wjg.v10.i9.1315] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
121 Wijayagunawardane MPB, Wijerathne CUB, Herath CB. Indigenous Herbal Recipes for Treatment of Liver Cirrhosis. Procedia Chemistry 2015;14:270-6. [DOI: 10.1016/j.proche.2015.03.038] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
122 Kubo N, Furusyo N, Nakashima H, Kashiwagi K, Hayashi J. Strenuous physical labor is important as a cause of elevated alanine aminotransferase levels in Japanese patients with chronic hepatitis C viremia. Eur J Epidemiol. 2005;20:251-261. [PMID: 15921043 DOI: 10.1007/s10654-004-6516-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
123 Guo J, Loke J, Zheng F, Hong F, Yea S, Fukata M, Tarocchi M, Abar OT, Huang H, Sninsky JJ, Friedman SL. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology. 2009;49:960-968. [PMID: 19085953 DOI: 10.1002/hep.22697] [Cited by in Crossref: 147] [Cited by in F6Publishing: 148] [Article Influence: 11.3] [Reference Citation Analysis]
124 Lundbo LF, Clausen LN, Weis N, Schønning K, Rosenørn L, Benfield T, Christensen PB. Influence of hepatitis C virus and IL28B genotypes on liver stiffness. PLoS One 2014;9:e115882. [PMID: 25545640 DOI: 10.1371/journal.pone.0115882] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
125 Bacchetti P, Boylan R, Astemborski J, Shen H, Mehta SH, Thomas DL, Terrault NA, Monto A. Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One 2011;6:e20104. [PMID: 21637766 DOI: 10.1371/journal.pone.0020104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
126 Afsari A, Lee E, Shokrani B, Boortalary T, Sherif ZA, Nouraie M, Laiyemo AO, Alkhalloufi K, Brim H, Ashktorab H. Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C. Dig Dis Sci 2017;62:2159-65. [PMID: 28612194 DOI: 10.1007/s10620-017-4626-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
127 Persson EC, Schwartz LM, Park Y, Trabert B, Hollenbeck AR, Graubard BI, Freedman ND, McGlynn KA. Alcohol consumption, folate intake, hepatocellular carcinoma, and liver disease mortality. Cancer Epidemiol Biomarkers Prev. 2013;22:415-421. [PMID: 23307533 DOI: 10.1158/1055-9965-9965.epi-12-1169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther. 2016;44:877-889. [PMID: 27549244 DOI: 10.1111/apt.13770] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
129 Myers RP, Messous D, Poynard T, Imbert-Bismut F. Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C. Can J Gastroenterol 2007;21:289-94. [PMID: 17505564 DOI: 10.1155/2007/876076] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
130 Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, Welker M, Shi Y, Peveling-Oberhag J, Polta A, von Wagner M, Radeke HH, Sarrazin C, Trojan J, Zeuzem S, Kronenberger B, Piiper A. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One. 2011;6:e26971. [PMID: 22066022 DOI: 10.1371/journal.pone.0026971] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 9.5] [Reference Citation Analysis]
131 Chatterjee A, Swain MG, Lee SS, Bain VG, Peltekian K, Croitoru K, Adams PC, Kaita K, Teitel J, Heathcote EJ. Induction versus noninduction antiviral therapy for chronic hepatitis C virus in patients with congenital coagulation disorders: a Canadian multicentre trial. Can J Gastroenterol 2007;21:91-5. [PMID: 17299612 DOI: 10.1155/2007/817198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
132 Caraballo Cortes K, Zagordi O, Jabłońska J, Pawełczyk A, Kubisa N, Perlejewski K, Bukowska-Ośko I, Płoski R, Radkowski M, Laskus T. Spouse-to-Spouse Transmission and Evolution of Hypervariable Region 1 and 5' Untranslated Region of Hepatitis C Virus Analyzed by Next-Generation Sequencing. PLoS One 2016;11:e0150311. [PMID: 26918636 DOI: 10.1371/journal.pone.0150311] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
133 Lai JC, Verna EC, Brown RS, O’Leary JG, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, Terrault NA. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology. 2011;54:418-424. [PMID: 21538434 DOI: 10.1002/hep.24390] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
134 Ydreborg M, Lisovskaja V, Lagging M, Brehm Christensen P, Langeland N, Buhl MR, Pedersen C, Mørch K, Wejstål R, Norkrans G, Lindh M, Färkkilä M, Westin J. A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. PLoS One 2014;9:e93601. [PMID: 24699777 DOI: 10.1371/journal.pone.0093601] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
135 Gonik B. The role of obstetrician/gynecologists in the management of hepatitis C virus infection. Infect Dis Obstet Gynecol 2008;2008:374517. [PMID: 18818775 DOI: 10.1155/2008/374517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
136 Dickson KM, Martins PN. Implications of liver donor age on ischemia reperfusion injury and clinical outcomes. Transplant Rev (Orlando) 2020;34:100549. [PMID: 32498978 DOI: 10.1016/j.trre.2020.100549] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, Morimoto Y, Hashimoto N, Sakaguchi K, Sakata T, Ando M, Makino Y, Matsumura S, Takayama H, Seki H, Nanba S, Moritou Y, Yasunaka T, Ohnishi H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K. Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol 2015; 7(19): 2220-2228 [PMID: 26380048 DOI: 10.4254/wjh.v7.i19.2220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
138 Tamaki N, Kurosaki M, Higuchi M, Takada H, Nakakuki N, Yasui Y, Suzuki S, Tsuchiya K, Nakanishi H, Itakura J. Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. PLoS One. 2015;10:e0137351. [PMID: 26352693 DOI: 10.1371/journal.pone.0137351] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
139 Varma V, Webb K, Mirza DF. Liver transplantation for alcoholic liver disease. World J Gastroenterol 2010; 16(35): 4377-4393 [PMID: 20845504 DOI: 10.3748/wjg.v16.i35.4377] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
140 Koyama M, Nagai H, Bando K, Ito M, Moriyama Y, Emi M. Localization of a target region of allelic loss to a 1-cM interval on chromosome 16p.13.13 in hepatocellular carcinoma. Jpn J Cancer Res. 1999;90:951-956. [PMID: 10551323 DOI: 10.1111/j.1349-7006.1999.tb00840.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
141 Agha A, Chakik R, Abdulhadi Ali MM, Alsaudi D, Sammito G, Giannini EG. Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia. Ann Saudi Med 2013;33:610-3. [PMID: 24413867 DOI: 10.5144/0256-4947.2013.610] [Reference Citation Analysis]
142 Bacchetti P, Tien PC, Seaberg EC, O'Brien TR, Augenbraun MH, Kral AH, Busch MP, Edlin BR. Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis 2007;7:145. [PMID: 18070362 DOI: 10.1186/1471-2334-7-145] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
143 White DL, Richardson PA, Al-Saadi M, Fitzgerald SJ, Green L, Amaratunge C, Anand M, El-Serag HB. Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection. Dig Dis Sci 2011;56:1835-47. [PMID: 21188525 DOI: 10.1007/s10620-010-1505-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
144 Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun. 2015;6:6422. [PMID: 25740255 DOI: 10.1038/ncomms7422] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 17.3] [Reference Citation Analysis]
145 Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002;76:2997-3006. [PMID: 11861865 DOI: 10.1128/jvi.76.6.2997-3006.2002] [Cited by in Crossref: 311] [Cited by in F6Publishing: 149] [Article Influence: 15.6] [Reference Citation Analysis]
146 Marotta P, Bailey R, Elkashab M, Farley J, Feinman SV, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C. Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. Eur J Clin Microbiol Infect Dis 2016;35:597-609. [PMID: 26851949 DOI: 10.1007/s10096-016-2576-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
147 Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. J Viral Hepat 2015;22:175-83. [PMID: 25040391 DOI: 10.1111/jvh.12278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
148 Carroll SS, Ludmerer S, Handt L, Koeplinger K, Zhang NR, Graham D, Davies ME, MacCoss M, Hazuda D, Olsen DB. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 2009;53:926-34. [PMID: 19075052 DOI: 10.1128/AAC.01032-08] [Cited by in Crossref: 69] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
149 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Cited by in Crossref: 205] [Cited by in F6Publishing: 199] [Article Influence: 22.8] [Reference Citation Analysis]
150 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
151 Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006;55:569-78. [PMID: 16531536 DOI: 10.1136/gut.2005.084475] [Cited by in Crossref: 275] [Cited by in F6Publishing: 246] [Article Influence: 17.2] [Reference Citation Analysis]
152 Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134. [PMID: 26441826 DOI: 10.3389/fendo.2015.00134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 6.7] [Reference Citation Analysis]
153 Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Nagase T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Imai Y, Kato M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol 2011;46:944-52. [PMID: 21552988 DOI: 10.1007/s00535-011-0403-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
154 Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol 2015; 7(26): 2676-2680 [PMID: 26609344 DOI: 10.4254/wjh.v7.i26.2676] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 8.9] [Reference Citation Analysis]
155 Jonsson JR, Purdie DM, Clouston AD, Powell EE. Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. Mol Diagn Ther 2008;12:209-18. [PMID: 18652517 DOI: 10.1007/BF03256286] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
156 Mohan P, Colvin C, Glymph C, Chandra RR, Kleiner DE, Patel KM, Luban NL, Alter HJ. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr. 2007;150:168-174, 174.e1. [PMID: 17236895 DOI: 10.1016/j.jpeds.2006.11.037] [Cited by in Crossref: 64] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
157 Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1-16. [PMID: 16436109 DOI: 10.1111/j.0959-9673.2006.00465.x] [Cited by in Crossref: 487] [Cited by in F6Publishing: 482] [Article Influence: 30.4] [Reference Citation Analysis]
158 Ahumada A, Rayón L, Usón C, Bañares R, Alonso Lopez S. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J Gastroenterol 2021; 27(40): 6737-6749 [PMID: 34790004 DOI: 10.3748/wjg.v27.i40.6737] [Reference Citation Analysis]
159 Evon DM, Golin CE, Fried MW, Keefe FJ. Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? J Consult Clin Psychol 2013;81:361-74. [PMID: 22730952 DOI: 10.1037/a0029030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
160 Ismail MH, Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol. 2009;15:72-79. [PMID: 19568569 DOI: 10.4103/1319-3767.45072] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 4.8] [Reference Citation Analysis]
161 Silva MJ, Calinas F. Spontaneous clearance of hepatitis C virus during alcoholic hepatitis: the alcohol killed the virus? BMJ Case Rep 2015;2015:bcr2015211896. [PMID: 26483390 DOI: 10.1136/bcr-2015-211896] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
162 Trifan A, Stanciu C. Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol 2012; 18(39): 5514-5520 [PMID: 23112543 DOI: 10.3748/wjg.v18.i39.5514] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
163 Rodriguez B, Bobak DA. Management of Hepatitis C in HIV-infected Patients. Curr Infect Dis Rep. 2005;7:91-102. [PMID: 15727735 DOI: 10.1007/s11908-005-0067-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
164 Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, Pradat P, Thursz M; HENCORE collaboration. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003;52:574-9. [PMID: 12631672 DOI: 10.1136/gut.52.4.574] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 4.9] [Reference Citation Analysis]
165 Halász T, Horváth G, Pár G, Werling K, Kiss A, Schaff Z, Lendvai G. miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan. World J Gastroenterol 2015; 21(25): 7814-7823 [PMID: 26167081 DOI: 10.3748/wjg.v21.i25.7814] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
166 Thompson AJ, Holmes JA. Treating hepatitis C - what's new? Aust Prescr 2015;38:191-7. [PMID: 26843711 DOI: 10.18773/austprescr.2015.068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
167 Ashraf H, Alam NH, Rothermundt C, Brooks A, Bardhan P, Hossain L, Salam MA, Hassan MS, Beglinger C, Gyr N. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis. 2010;10:208. [PMID: 20630111 DOI: 10.1186/1471-2334-10-208] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
168 D'Souza R, Foster GR. Diagnosis and treatment of hepatitis C. J R Soc Med 2004;97:223-5. [PMID: 15121811 DOI: 10.1258/jrsm.97.5.223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
169 Viganò L, Jaffary SA, Ferrero A, Russolillo N, Langella S, Capussotti L. Liver resection without pedicle clamping: feasibility and need for "salvage clamping". Looking for the right clamping policy. Analysis of 512 consecutive resections. J Gastrointest Surg 2011;15:1820-8. [PMID: 21809167 DOI: 10.1007/s11605-011-1625-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
170 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562. [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107] [Cited by in Crossref: 625] [Cited by in F6Publishing: 583] [Article Influence: 69.4] [Reference Citation Analysis]
171 Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Goto T, Yoshida H, Kanai F, Sugioka Y, Ikeda H, Shiina S, Kawabe T, Omata M. Comparison of liver biopsy and transient elastography based on clinical relevance. Can J Gastroenterol 2008;22:753-7. [PMID: 18818788 DOI: 10.1155/2008/306726] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
172 Amodio P, Salari L, Montagnese S, Schiff S, Neri D, Bianco T, Minazzato L. Hepatitis C virus infection and health-related quality of life. World J Gastroenterol 2012; 18(19): 2295-2299 [PMID: 22654420 DOI: 10.3748/wjg.v18.i19.2295] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
173 Wake T, Tateishi R, Fukumoto T, Nakagomi R, Kinoshita MN, Nakatsuka T, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Fujinaga H, Asaoka Y, Tanaka Y, Otsuka M, Koike K. Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume. PLoS One 2020;15:e0231836. [PMID: 32310974 DOI: 10.1371/journal.pone.0231836] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Marquardt JU, Seo D, Gómez-Quiroz LE, Uchida K, Gillen MC, Kitade M, Kaposi-Novak P, Conner EA, Factor VM, Thorgeirsson SS. Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways. Biochim Biophys Acta. 2012;1822:942-951. [PMID: 22386877 DOI: 10.1016/j.bbadis.2012.02.012] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
175 Sharma SA, Feld JJ. Management of HCV in cirrhosis-a rapidly evolving landscape. Curr Gastroenterol Rep 2015;17:443. [PMID: 25896437 DOI: 10.1007/s11894-015-0443-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
176 Arteel GE. Silencing a killer among us: ethanol impairs immune surveillance of activated stellate cells by natural killer cells. Gastroenterology. 2008;134:351-353. [PMID: 18166364 DOI: 10.1053/j.gastro.2007.11.061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
177 Miyasaka A, Yoshida Y, Yoshida T, Murakami A, Abe K, Ohuchi K, Kawakami T, Watanabe D, Hoshino T, Sawara K, Takikawa Y. The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1. Intern Med 2018;57:2807-12. [PMID: 29780135 DOI: 10.2169/internalmedicine.0810-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
178 Mendes LS, Nita ME, Ono-Nita SK, Mello ES, Silva LCD, Alves VA, Carrilho FJ. Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients. World J Gastroenterol 2008; 14(16): 2522-2528 [PMID: 18442199 DOI: 10.3748/wjg.14.2522] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
179 Horvat T, Landesmann B, Lostia A, Vinken M, Munn S, Whelan M. Adverse outcome pathway development from protein alkylation to liver fibrosis. Arch Toxicol 2017;91:1523-43. [PMID: 27542122 DOI: 10.1007/s00204-016-1814-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
180 Yasui K, Kawaguchi T, Shima T, Mitsuyoshi H, Seki K, Sendo R, Mizuno M, Itoh Y, Matsuda F, Okanoue T. Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C. J Gastroenterol. 2015;50:887-893. [PMID: 25543233 DOI: 10.1007/s00535-014-1018-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
181 Ariyasu T, Tanaka T, Fujioka N, Yanai Y, Yamamoto S, Yamauchi H, Ikegami H, Ikeda M, Kurimoto M. Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders. In Vitro Cell Dev Biol Anim. 2005;41:50-56. [PMID: 15926860 DOI: 10.1290/0501008.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
182 De Nicola S, Dongiovanni P, Aghemo A, Cheroni C, D'Ambrosio R, Pedrazzini M, Marabita F, Donnici L, Maggioni M, Fargion S, Colombo M, De Francesco R, Valenti L. Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C. PLoS One 2014;9:e106022. [PMID: 25171251 DOI: 10.1371/journal.pone.0106022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
183 Guido M, Fagiuoli S, Tessari G, Burra P, Leandro G, Boccagni P, Cillo U, Naccarato R, Rugge M. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002;50:697-700. [PMID: 11950819 DOI: 10.1136/gut.50.5.697] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
184 Spiegelman D, Lovato LC, Khudyakov P, Wilkens TL, Adebamowo CA, Adebamowo SN, Appel LJ, Beulens JW, Coughlin JW, Dragsted LO, Edenberg HJ, Eriksen JN, Estruch R, Grobbee DE, Gulayin PE, Irazola V, Krystal JH, Lazo M, Murray MM, Rimm EB, Schrieks IC, Williamson JD, Mukamal KJ. The Moderate Alcohol and Cardiovascular Health Trial (MACH15): Design and methods for a randomized trial of moderate alcohol consumption and cardiometabolic risk. Eur J Prev Cardiol 2020;27:1967-82. [PMID: 32250171 DOI: 10.1177/2047487320912376] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
185 Paisant A, Boulic A, Bardou-Jacquet E, Bannier E, d'Assignies G, Lainé F, Turlin B, Gandon Y. Assessment of liver iron overload by 3 T MRI. Abdom Radiol (NY) 2017;42:1713-20. [PMID: 28224171 DOI: 10.1007/s00261-017-1077-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
186 Chang RH, Nyamsuren T, Gyawali S, Fu SC, Huang YW, Hu RT, Yang SS. Long-term Nucleos(t)ides Analogues for Chronic Hepatitis B Improve Liver and Spleen Size: A Noninvasive Sonographic Study. J Med Ultrasound 2017;25:161-6. [PMID: 30065482 DOI: 10.1016/j.jmu.2017.03.013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
187 White DL, Tavakoli-Tabasi S, Kuzniarek J, Ramsey DJ, El-Serag HB. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease. J Clin Gastroenterol 2012;46:779-88. [PMID: 22955261 DOI: 10.1097/MCG.0b013e318266f6eb] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
188 Stankovic Z. Four-dimensional flow magnetic resonance imaging in cirrhosis. World J Gastroenterol 2016; 22(1): 89-102 [PMID: 26755862 DOI: 10.3748/wjg.v22.i1.89] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
189 Issa H. Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia. World J Hepatol 2010; 2(5): 180-184 [PMID: 21160993 DOI: 10.4254/wjh.v2.i5.180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
190 Patil R, Cotler SJ, Banaad-Omiotek G, McNutt RA, Brown MD, Cotler S, Jensen DM. Physicians' preference values for hepatitis C health states and antiviral therapy: a survey. BMC Gastroenterol 2001;1:6. [PMID: 11513756 DOI: 10.1186/1471-230x-1-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
191 Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, O'Keane JC, Crowe J. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut. 2001;49:423-430. [PMID: 11511566 DOI: 10.1136/gut.49.3.423] [Cited by in Crossref: 107] [Cited by in F6Publishing: 103] [Article Influence: 5.1] [Reference Citation Analysis]
192 Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, Muss N, Sandhofer F, Vogel W. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999;44:563-7. [PMID: 10075966 DOI: 10.1136/gut.44.4.563] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.1] [Reference Citation Analysis]
193 Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC; Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004;53:451-455. [PMID: 14960533 DOI: 10.1136/gut.2003.021691] [Cited by in Crossref: 193] [Cited by in F6Publishing: 188] [Article Influence: 10.7] [Reference Citation Analysis]
194 Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies. Dig Dis Sci 2003;48:1654-7. [PMID: 12924664 DOI: 10.1023/a:1024796630509] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
195 Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014; 20(45): 16820-16830 [PMID: 25492996 DOI: 10.3748/wjg.v20.i45.16820] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 67] [Article Influence: 11.6] [Reference Citation Analysis]
196 Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008;12:939-62, xi. [PMID: 18984475 DOI: 10.1016/j.cld.2008.07.011] [Cited by in Crossref: 112] [Cited by in F6Publishing: 108] [Article Influence: 8.6] [Reference Citation Analysis]
197 Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-218. [PMID: 15690074 DOI: 10.1172/jci200524282] [Cited by in Crossref: 211] [Cited by in F6Publishing: 15] [Article Influence: 12.4] [Reference Citation Analysis]
198 Sasaki Y, Ohfuji S, Fukushima W, Tamori A, Enomoto M, Habu D, Iwai S, Uchida-Kobayashi S, Fujii H, Shiomi S, Kawada N, Hirota Y. Effect of caffeine-containing beverage consumption on serum alanine aminotransferase levels in patients with chronic hepatitis C virus infection: a hospital-based cohort study. PLoS One 2013;8:e83382. [PMID: 24349501 DOI: 10.1371/journal.pone.0083382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
199 Kawano T, Murata M, Hyodo F, Eto H, Kosem N, Nakata R, Hamano N, Piao JS, Narahara S, Akahoshi T, Hashizume M. Noninvasive mapping of the redox status of dimethylnitrosamine-induced hepatic fibrosis using in vivo dynamic nuclear polarization-magnetic resonance imaging. Sci Rep 2016;6:32604. [PMID: 27587186 DOI: 10.1038/srep32604] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
200 Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci. 2003;48:146-153. [PMID: 12645802 DOI: 10.1023/a:1021702902681] [Cited by in Crossref: 56] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
201 Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005;106:1175-82. [PMID: 15860662 DOI: 10.1182/blood-2005-01-0126] [Cited by in Crossref: 130] [Cited by in F6Publishing: 124] [Article Influence: 7.6] [Reference Citation Analysis]
202 Jiang KP, Li JH, Hu HT, Ren J, Qiu TY, Huang QH, Mao RJ. FibroScan vs hepatic histopathology for diagnosis of liver fibrosis in chronic hepatitis B patients with liver stagnation and spleen deficiency syndrome or damp and heat accumulation syndrome. Shijie Huaren Xiaohua Zazhi 2014; 22(19): 2768-2773 [DOI: 10.11569/wcjd.v22.i19.2768] [Reference Citation Analysis]
203 Mascheretti S, Hinrichsen H, Ross S, Buggisch P, Hampe J, Foelsch UR, Schreiber S. Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exp Immunol. 2004;136:328-333. [PMID: 15086398 DOI: 10.1111/j.1365-2249.2004.02444.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
204 Attallah AM, Omran MM, Attallah AA, Abdallah SO, Farid K, Darwish H, El-Dosoky I, Shaker YM. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer 2013;109:1657-65. [PMID: 23982602 DOI: 10.1038/bjc.2013.481] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
205 Kaibori M, Kubo S, Nagano H, Hayashi M, Haji S, Nakai T, Ishizaki M, Matsui K, Uenishi T, Takemura S, Wada H, Marubashi S, Komeda K, Hirokawa F, Nakata Y, Uchiyama K, Kwon A. Clinicopathological Features of Recurrence in Patients After 10-year Disease-free Survival Following Curative Hepatic Resection of Hepatocellular Carcinoma. World J Surg 2013;37:820-8. [DOI: 10.1007/s00268-013-1902-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
206 Masuzaki R, Tateishi R, Yoshida H, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Asaoka Y, Kondo Y, Goto T, Ikeda H, Shiina S, Omata M, Koike K. Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography. World J Gastroenterol 2012; 18(12): 1385-1390 [PMID: 22493553 DOI: 10.3748/wjg.v18.i12.1385] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
207 Gurusamy KS, Wilson E, Koretz RL, Allen VB, Davidson BR, Burroughs AK, Gluud C. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention? PLoS One. 2013;8:e83313. [PMID: 24349487 DOI: 10.1371/journal.pone.0083313] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
208 Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;42:513-521. [PMID: 17653645 DOI: 10.1007/s00535-007-2064-6] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 8.5] [Reference Citation Analysis]
209 Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP, Dusheiko G, Davidson B, Rolles K, Burroughs AK. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut. 1999;45:427-434. [PMID: 10446114 DOI: 10.1136/gut.45.3.427] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 2.2] [Reference Citation Analysis]
210 Marticorena Garcia SR, Althoff CE, Dürr M, Halleck F, Budde K, Grittner U, Burkhardt C, Jöhrens K, Braun J, Fischer T, Hamm B, Sack I, Guo J. Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection. J Clin Med 2021;10:510. [PMID: 33535495 DOI: 10.3390/jcm10030510] [Reference Citation Analysis]
211 Burman BE, Bacchetti P, Khalili M. Moderate Alcohol Use and Insulin Action in Chronic Hepatitis C Infection. Dig Dis Sci 2016;61:2417-25. [PMID: 27007134 DOI: 10.1007/s10620-016-4119-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
212 Gaggini MC, Navarro RS, Stefanini AR, Sano RS, Silveira L Jr. Correlation between METAVIR scores and Raman spectroscopy in liver lesions induced by hepatitis C virus: a preliminary study. Lasers Med Sci 2015;30:1347-55. [PMID: 25794591 DOI: 10.1007/s10103-015-1741-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
213 Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050-68. [PMID: 11106350 [PMID: 11106350 DOI: 10.1093/clinchem/46.12.2050] [Cited by in Crossref: 213] [Cited by in F6Publishing: 105] [Article Influence: 10.1] [Reference Citation Analysis]
214 Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011644. [PMID: 28285495 DOI: 10.1002/14651858.CD011644.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
215 Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 2010;8:1002-12. [PMID: 20851211 DOI: 10.1016/j.cgh.2010.08.024] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 9.4] [Reference Citation Analysis]
216 Tran HA, Jones TL, Ianna EA, Foy A, Reeves GE. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract 2013;19:292-300. [PMID: 23186968 DOI: 10.4158/EP12195.RA] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
217 Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, Iino S, Makino I, Okita K, Toda G, Tanikawa K, Kumada H; Japanese C-Viral Hepatitis Network. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007;56:1747-53. [PMID: 17573387 DOI: 10.1136/gut.2007.120956] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
218 Attallah AM, El-Far M, Omran MM, Farid K, Albannan MS, El-Dosoky I. Noninvasive diagnosis of liver fibrosis and cirrhosis in chronic hepatitis C patients. J Clin Lab Anal 2013;27:121-9. [PMID: 23460258 DOI: 10.1002/jcla.21572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
219 Sterling RK, Wegelin JA, Smith PG, Stravitz RT, Luketic VA, Fuchs M, Puri P, Shiffman ML, Contos MA, Mills AS. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol. 2010;8:1070-1076. [PMID: 20728569 DOI: 10.1016/j.cgh.2010.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
220 Mattingly TJ 2nd, Slejko JF, Onukwugha E, Perfetto EM, Kottilil S, Mullins CD. Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. Pharmacoeconomics 2020;38:233-42. [PMID: 31788751 DOI: 10.1007/s40273-019-00864-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
221 Meriden Z, Forde KA, Pasha TL, Hui JJ, Reddy KR, Furth EE, Wells RG. Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010;8:289-296, 296.e1-8. [PMID: 19913638 DOI: 10.1016/j.cgh.2009.10.034] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
222 Fernández-Rodriguez CM, Gutiérrez ML, Serrano PL, Lledó JL, Santander C, Fernández TP, Tomás E, Cacho G, Nevado M, Casas ML. Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci. 2004;49:1971-1976. [PMID: 15628736 DOI: 10.1007/s10620-004-9603-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
223 Motawi TK, Shaker OG, El-Maragh SA, Senousy MA. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients. PLOS One. 2015;10:e0137706. [PMID: 26352740 DOI: 10.1371/journal.pone.0137706] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
224 Nguyen JT, Rich JD, Brockmann BW, Vohr F, Spaulding A, Montague BT. A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System. J Urban Health 2015;92:635-49. [PMID: 25828149 DOI: 10.1007/s11524-015-9953-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
225 Osna NA, Carter WG, Ganesan M, Kirpich IA, McClain CJ, Petersen DR, Shearn CT, Tomasi ML, Kharbanda KK. Aberrant post-translational protein modifications in the pathogenesis of alcohol-induced liver injury. World J Gastroenterol 2016; 22(27): 6192-6200 [PMID: 27468209 DOI: 10.3748/wjg.v22.i27.6192] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
226 Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-1569. [PMID: 11029989 DOI: 10.2105/ajph.90.10.1562] [Cited by in Crossref: 409] [Cited by in F6Publishing: 130] [Article Influence: 18.6] [Reference Citation Analysis]
227 Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Hüppe D, Böker K, Wedemeyer H, Welzel TM; Leberstiftungs-GmbH Deutschland. Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. Drugs Aging 2018;35:843-57. [PMID: 30084012 DOI: 10.1007/s40266-018-0572-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
228 Yang Y, Liu H. Association between interleukin-18 gene promoter (- 607C/A and - 137G/C) polymorphisms and chronic hepatitis C virus infections: A meta-analysis. Meta Gene 2015;5:21-31. [PMID: 26042207 DOI: 10.1016/j.mgene.2015.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
229 Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 14.4] [Reference Citation Analysis]
230 Tang AM, Sheehan HB, Jordan MR, Duong DV, Terrin N, Dong K, Lien TT, Trung NV, Wanke CA, Hien ND. Predictors of Weight Change in Male HIV-Positive Injection Drug Users Initiating Antiretroviral Therapy in Hanoi, Vietnam. AIDS Res Treat 2011;2011:890308. [PMID: 21776380 DOI: 10.1155/2011/890308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
231 Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol 2015; 7(14): 1843-1855 [PMID: 26207166 DOI: 10.4254/wjh.v7.i14.1843] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
232 Sajja KC, Mohan DP, Rockey DC. Age and ethnicity in cirrhosis. J Investig Med 2014;62:920-6. [PMID: 25203153 DOI: 10.1097/JIM.0000000000000106] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
233 George J. Biochemical markers of hepatic fibrogenesis: Single measurements are not reliable enough to replace liver biopsy. Journal of Gastroenterology and Hepatology 2001;15:819-21. [DOI: 10.1046/j.1440-1746.2000.02175.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
234 Lipman MM, Cotler SJ. Antiviral Therapy for Hepatitis C. Curr Treat Options Gastroenterol 2003;6:445-53. [PMID: 14585233 DOI: 10.1007/s11938-003-0046-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
235 Lo Iacono O, Castro A, Diago M, Moreno JA, Fernandez-Bermejo M, Vega P, García V, Carbonell P, Sanz P, Borque MJ, García-Buey L, García-Monzón C, Pedreira J, Moreno-Otero R. Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. Aliment Pharmacol Ther 2000;14:463-9. [PMID: 10759626 DOI: 10.1046/j.1365-2036.2000.00713.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
236 Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Mehmedovic A, Junuzovic D, Bjelogrlic I, Sofic A, Djurovic A. Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. Mater Sociomed. 2014;26:172-176. [PMID: 25126010 DOI: 10.5455/msm.2014.26.172-176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
237 Berenguer M, Wright TL. Hepatitis C and liver transplantation. Gut. 1999;45:159-163. [PMID: 10403720 DOI: 10.1136/gut.45.2.159] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 1.1] [Reference Citation Analysis]
238 Dong CF, Xiao J, Shan LB, Li HY, Xiong YJ, Yang GL, Liu J, Yao SM, Li SX, Le XH, Yuan J, Zhou BP, Tipoe GL, Liu YX. Combined acoustic radiation force impulse, aminotransferase to platelet ratio index and Forns index assessment for hepatic fibrosis grading in hepatitis B. World J Hepatol 2016; 8(14): 616-624 [PMID: 27190578 DOI: 10.4254/wjh.v8.i14.616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
239 Altamirano J, Michelena J. Alcohol consumption as a cofactor for other liver diseases. Clin Liver Dis (Hoboken) 2013;2:72-5. [PMID: 30992828 DOI: 10.1002/cld.197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
240 Yang L, Rudser KD, Higgins L, Rosen HR, Zaman A, Corless CL, David L, Gourley GR. Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics. Dig Dis Sci. 2011;56:3305-3315. [PMID: 21590334 DOI: 10.1007/s10620-011-1745-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
241 Hosoi H, Warigaya K, Murata S, Mushino T, Kuriyama K, Nishikawa A, Tamura S, Hatanaka K, Hanaoka N, Muragaki Y, Murata S, Nakakuma H, Sonoki T. Refractory Ascites with Liver Fibrosis Developed in Late Phase Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Patients. Hematol Rep 2016;8:6482. [PMID: 27499838 DOI: 10.4081/hr.2016.6482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
242 Calès P, Chaigneau J, Hunault G, Michalak S, Cavaro-Menard C, Fasquel JB, Bertrais S, Rousselet MC. Automated morphometry provides accurate and reproducible virtual staging of liver fibrosis in chronic hepatitis C. J Pathol Inform 2015;6:20. [PMID: 26110088 DOI: 10.4103/2153-3539.157782] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
243 Esmaeili A, Yu W, Cucciare MA, Combs AS, Joshi G, Humphreys K. Budget Impact Analysis of a Computer-Delivered Brief Alcohol Intervention in Veterans Affairs (VA) Liver Clinics: A Randomized Controlled Trial. Alcoholism Treatment Quarterly 2020;38:515-31. [DOI: 10.1080/07347324.2020.1760755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 McCarthy M, Wilkinson ML. Recent advances: hepatology. BMJ 1999;318:1256-9. [PMID: 10231259 DOI: 10.1136/bmj.318.7193.1256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
245 Cheng PN, Chiu HC, Chiu YC, Chen SC, Chen Y. Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community. PLoS One 2018;13:e0206947. [PMID: 30403744 DOI: 10.1371/journal.pone.0206947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
246 Rumi MG, De Filippi F, La Vecchia C, Donato MF, Gallus S, Del Ninno E, Colombo M. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut. 2005;54:402-406. [PMID: 15710990 DOI: 10.1136/gut.2004.048009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
247 Tan YW, Tao Y, Liu LG, Ye Y, Zhou XB, Chen L, He C. Epidemiological features of chronic hepatitis C infection caused by remunerated blood donors: A nearly 27-year period survey. World J Gastroenterol 2018; 24(11): 1250-1258 [PMID: 29568205 DOI: 10.3748/wjg.v24.i11.1250] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
248 Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162:619-29. [PMID: 25820703 DOI: 10.7326/M14-1313] [Cited by in Crossref: 76] [Cited by in F6Publishing: 41] [Article Influence: 10.9] [Reference Citation Analysis]
249 Erman A, Krahn MD, Hansen T, Wong J, Bielecki JM, Feld JJ, Wong WWL, Grootendorst P, Thein HH. Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. BMJ Open 2019;9:e027491. [PMID: 31719068 DOI: 10.1136/bmjopen-2018-027491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
250 Yu JS, Shim JH, Chung JJ, Kim JH, Kim KW. Double contrast-enhanced MRI of viral hepatitis-induced cirrhosis: correlation of gross morphological signs with hepatic fibrosis. Br J Radiol. 2010;83:212-217. [PMID: 19505965 DOI: 10.1259/bjr/70974553] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
251 Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B, Romagnani P, Milani S, Ginés P. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol. 2006;169:2042-2053. [PMID: 17148667 DOI: 10.2353/ajpath] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
252 Ke PY, Chen SSL. Autophagy in hepatitis C virus-host interactions: Potential roles and therapeutic targets for liver-associated diseases. World J Gastroenterol 2014; 20(19): 5773-5793 [PMID: 24914338 DOI: 10.3748/wjg.v20.i19.5773] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
253 Noworolski SM, Tien PC, Merriman R, Vigneron DB, Qayyum A. Respiratory motion-corrected proton magnetic resonance spectroscopy of the liver. Magn Reson Imaging 2009;27:570-6. [PMID: 18993007 DOI: 10.1016/j.mri.2008.08.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
254 Mehta SH, McFall AM, Srikrishnan AK, Kumar MS, Nandagopal P, Cepeda J, Thomas DL, Sulkowski MS, Solomon SS. Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India. Open Forum Infect Dis 2016;3:ofw121. [PMID: 27419185 DOI: 10.1093/ofid/ofw121] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
255 Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009;54:1317-1324. [PMID: 18958621 DOI: 10.1007/s10620-008-0500y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
256 Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-856 [PMID: 28740596 DOI: 10.4254/wjh.v9.i19.850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
257 Smith D, Magri A, Bonsall D, Ip CLC, Trebes A, Brown A, Piazza P, Bowden R, Nguyen D, Ansari MA, Simmonds P, Barnes E; STOP-HCV Consortium. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology 2019;69:1861-72. [PMID: 29425396 DOI: 10.1002/hep.29837] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
258 Wörns MA, Galle PR, Zeuzem S, Schirmacher P, Manns M, Vogel A. Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. Dtsch Arztebl Int 2017;114:597-602. [PMID: 28927498 DOI: 10.3238/arztebl.2017.0597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
259 Takahashi H, Mizuta T, Eguchi Y, Kawaguchi Y, Kuwashiro T, Oeda S, Isoda H, Oza N, Iwane S, Izumi K. Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol. 2011;46:790-798. [PMID: 21331763 DOI: 10.1007/s00535-011-0381-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
260 Bichoupan K, Tandon N, Martel-Laferriere V, Patel NM, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Olson W, Perumalswami PV, Schiano TD, Odin JA, Liu LU, Dieterich DT, Branch AD. Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World J Hepatol 2017; 9(11): 551-561 [PMID: 28469811 DOI: 10.4254/wjh.v9.i11.551] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
261 Kim H, Chung YK, Kim I. Recognition criteria for occupational cancers in relation to hepatitis B virus and hepatitis C virus in Korea. Ann Occup Environ Med 2018;30:6. [PMID: 29423229 DOI: 10.1186/s40557-018-0217-0] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
262 Verloh N, Einspieler I, Utpatel K, Menhart K, Brunner S, Hofheinz F, van den Hoff J, Wiggermann P, Evert M, Stroszczynski C, Hellwig D, Grosse J. In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT. EJNMMI Res 2018;8:98. [PMID: 30414009 DOI: 10.1186/s13550-018-0452-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
263 Song ATW, Sobesky R, Vinaixa C, Dumortier J, Radenne S, Durand F, Calmus Y, Rousseau G, Latournerie M, Feray C, Delvart V, Roche B, Haim-Boukobza S, Roque-Afonso AM, Castaing D, Abdala E, D’Albuquerque LAC, Duclos-Vallée JC, Berenguer M, Samuel D. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. World J Gastroenterol 2016; 22(18): 4547-4558 [PMID: 27182164 DOI: 10.3748/wjg.v22.i18.4547] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
264 Beld M, Penning M, McMorrow M, Gorgels J, van den Hoek A, Goudsmit J. Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels. J Clin Microbiol 1998;36:872-7. [PMID: 9542901 DOI: 10.1128/JCM.36.4.872-877.1998] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
265 Morgan JR, Kim AY, Naggie S, Linas BP. The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets. Open Forum Infect Dis 2018;5:ofx267. [PMID: 29354660 DOI: 10.1093/ofid/ofx267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
266 Sood A, Suryaprasad A, Trickey A, Kanchi S, Midha V, Foster MA, Bennett E, Kamili S, Alvarez-Bognar F, Shadaker S, Surlikar V, Garg R, Mittal P, Sharma S, May MT, Vickerman P, Averhoff F. The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey. PLoS One 2018;13:e0200461. [PMID: 30048454 DOI: 10.1371/journal.pone.0200461] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
267 Decaris ML, Emson CL, Li K, Gatmaitan M, Luo F, Cattin J, Nakamura C, Holmes WE, Angel TE, Peters MG, Turner SM, Hellerstein MK. Turnover rates of hepatic collagen and circulating collagen-associated proteins in humans with chronic liver disease. PLoS One 2015;10:e0123311. [PMID: 25909381 DOI: 10.1371/journal.pone.0123311] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
268 Combellick J, Smith DJ, Jordan AE, Hagan H. Hepatitis C Virus Disease Progression in People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc 2015;4:e68. [PMID: 26054636 DOI: 10.2196/resprot.4518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
269 Ogawa E, Kawano A, Ooho A, Furusyo N, Satoh T, Takahashi K, Kajiwara E, Dohmen K, Nakamuta M, Azuma K, Koyanagi T, Yamashita N, Yanagita K, Ichiki Y, Kuniyoshi M, Yamashita N, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection. J Gastroenterol Hepatol 2021. [PMID: 34618379 DOI: 10.1111/jgh.15703] [Reference Citation Analysis]
270 Thorburn D, Curry G, Spooner R, Spence E, Oien K, Halls D, Fox R, McCruden EA, MacSween RN, Mills PR. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut. 2002;50:248-252. [PMID: 11788568 DOI: 10.1136/gut.50.2.248] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 4.3] [Reference Citation Analysis]
271 Flemming JA, Hurlbut DJ, Mussari B, Hookey LC. Liver biopsies for chronic hepatitis C: should nonultrasound-guided biopsies be abandoned? Can J Gastroenterol 2009;23:425-30. [PMID: 19543573 DOI: 10.1155/2009/370651] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
272 Wang TZ, Lin DD, Jin BX, Sun XY, Li N. Plasma microRNA: A novel non-invasive biomarker for HBV-associated liver fibrosis staging. Exp Ther Med. 2019;17:1919-1929. [PMID: 30783469 DOI: 10.3892/etm.2018.7117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
273 Oloruntoba OO, Moylan CA. Gender-based disparities in access to and outcomes of liver transplantation. World J Hepatol 2015; 7(3): 460-467 [PMID: 25848470 DOI: 10.4254/wjh.v7.i3.460] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
274 Ahmed AM, Hassan MS, Abd-Elsayed A, Hassan H, Hasanain AF, Helmy A. Insulin resistance, steatosis, and fibrosis in Egyptian patients with chronic Hepatitis C virus infection. Saudi J Gastroenterol. 2011;17:245-251. [PMID: 21727730 DOI: 10.4103/1319-3767.82578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
275 Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. Clinical outcomes of compensated and decompensated cirrhosis: A long term study. World J Hepatol 2014; 6(7): 504-512 [PMID: 25068002 DOI: 10.4254/wjh.v6.i7.504] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
276 Piccoli Lde Z, Mattos AA, Coral GP, Mattos AZ, Santos DE. Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis. Arq Gastroenterol 2011;48:179-85. [PMID: 21952702 DOI: 10.1590/s0004-28032011000300005] [Reference Citation Analysis]
277 Alboraie MA, Afifi ME, Elghamry FG, Shalaby HA, Elshennawy GE, Abdelaziz AA, Shaheen MU, Abo El-Seoud AR. Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study. Hepat Mon 2013;13:e10810. [PMID: 24046790 DOI: 10.5812/hepatmon.10810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
278 Jin YJ, Shim JH, Kim GA, Yu E, Kim KM, Lim YS, Lee HC. Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. BMJ Open 2014;4:e006255. [PMID: 25431223 DOI: 10.1136/bmjopen-2014-006255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
279 Blixen CE, Webster NJ, Hund AJ, Perzynski AT, Kanuch SW, Stoller EP, McCormick RA, Dawson NV. Communicating about alcohol consumption to nonharmful drinkers with hepatitis C: patient and provider perspectives. J Gen Intern Med 2008;23:242-7. [PMID: 18172739 DOI: 10.1007/s11606-007-0483-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
280 Kramer JR, El-Serag HB, Taylor TJ, White DL, Asch SM, Frayne SM, Cao Y, Smith DL, Kanwal F. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat 2017;24:955-65. [PMID: 28815822 DOI: 10.1111/jvh.12728] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
281 Tillmann HL. Hepatitis C virus infection and the brain. Metab Brain Dis 2004;19:351-6. [PMID: 15554427 DOI: 10.1023/b:mebr.0000043981.89134.39] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
282 Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002;55:689-92. [PMID: 12195000 DOI: 10.1136/jcp.55.9.689] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 3.5] [Reference Citation Analysis]
283 Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol Int 2016;10:749-61. [PMID: 27337961 DOI: 10.1007/s12072-016-9744-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
284 Campbell JV, Hagan H, Latka MH, Garfein RS, Golub ET, Coady MH, Thomas DL, Strathdee SA; STRIVE Project. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 2006;81:259-65. [PMID: 16129567 DOI: 10.1016/j.drugalcdep.2005.07.005] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 3.6] [Reference Citation Analysis]
285 Drumright LN, Hagan H, Thomas DL, Latka MH, Golub ET, Garfein RS, Clapp JD, Campbell JV, Bonner S, Kapadia F, Thiel TK, Strathdee SA. Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. J Hepatol 2011;55:45-52. [PMID: 21145862 DOI: 10.1016/j.jhep.2010.10.028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
286 Zhao H, Zhu P, Han T, Ye Q, Xu C, Wu L, Liu F, Yin W, Li Z, Guo Y. Clinical characteristics analysis of 1180 patients with hepatocellular carcinoma secondary to hepatitis B, hepatitis C and alcoholic liver disease. J Clin Lab Anal 2020;34:e23075. [PMID: 31659795 DOI: 10.1002/jcla.23075] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
287 Moessner BK, Andersen ES, Weis N, Laursen AL, Ingerslev J, Lethagen S, Pedersen C, Christensen PB. Previously unrecognized advanced liver disease unveiled by transient elastography in patients with Haemophilia and chronic hepatitis C. Haemophilia 2011;17:938-43. [PMID: 21435119 DOI: 10.1111/j.1365-2516.2011.02520.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
288 Kileng H, Gutteberg T, Goll R, Paulssen EJ. Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study. BMC Infect Dis 2019;19:189. [PMID: 30808290 DOI: 10.1186/s12879-019-3832-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
289 Gao QJ, Liu DW, Zhang SY, Jia M, Wang LM, Wu LH, Wang SY, Tong LX. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol 2009; 15(44): 5610-5619 [PMID: 19938203 DOI: 10.3748/wjg.15.5610] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 77] [Article Influence: 5.9] [Reference Citation Analysis]
290 Li C, Candotti D, Allain JP. Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1. J Virol. 2001;75:12412-12420. [PMID: 11711631 DOI: 10.1128/JVI.75.24.12412-12420.2001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
291 Inoue A, Obayashi K, Sonoda Y, Nakamura A, Ueno T, Kuhara S, Tashiro K. Regulation of matrix metalloproteinase-1 and alpha-smooth muscle actin expression by interleukin-1 alpha and tumour necrosis factor alpha in hepatic stellate cells. Cytotechnology 2017;69:461-8. [PMID: 26825680 DOI: 10.1007/s10616-016-9948-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
292 Kobayashi Y, Kawaguchi Y, Mizuta T, Kuwashiro T, Oeda S, Oza N, Takahashi H, Iwane S, Eguchi Y, Anzai K. Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C. J Gastroenterol. 2011;46:529-535. [PMID: 21046172 DOI: 10.1007/s00535-010-0338-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
293 Zeng QL, Feng GH, Zhang JY, Chen Y, Yang B, Huang HH, Zhang XX, Zhang Z, Wang FS. Risk factors for liver-related mortality in chronic hepatitis C patients: A deceased case-living control study. World J Gastroenterol 2014; 20(18): 5519-5526 [PMID: 24833882 DOI: 10.3748/wjg.v20.i18.5519] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
294 Tanaka K, Sakai H, Hashizume M, Hirohata T. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn J Cancer Res. 1998;89:1241-1250. [PMID: 10081484 DOI: 10.1111/j.1349-7006.1998.tb00520.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
295 Lara J, López-Labrador F, González-Candelas F, Berenguer M, Khudyakov YE. Computational models of liver fibrosis progression for hepatitis C virus chronic infection. BMC Bioinformatics 2014;15 Suppl 8:S5. [PMID: 25081062 DOI: 10.1186/1471-2105-15-S8-S5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
296 Jang H, Ryoo SR, Kim YK, Yoon S, Kim H, Han SW, Choi BS, Kim DE, Min DH. Discovery of hepatitis C virus NS3 helicase inhibitors by a multiplexed, high-throughput helicase activity assay based on graphene oxide. Angew Chem Int Ed Engl 2013;52:2340-4. [PMID: 23355441 DOI: 10.1002/anie.201209222] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
297 Trembling PM, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2014;21:430-8. [PMID: 24750297 DOI: 10.1111/jvh.12161] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
298 Lee HW, Yoo KY, Won JW, Kim HJ. Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced. Gut Liver 2017;11:721-7. [PMID: 28874040 DOI: 10.5009/gnl17209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
299 Sharif F, Mohebbi S, Tabatabaee HR, Saberi-Firoozi M, Gholamzadeh S. Effects of psycho-educational intervention on health-related quality of life (QOL) of patients with chronic liver disease referring to Shiraz University of Medical Sciences. Health Qual Life Outcomes. 2005;3:81. [PMID: 16356186 DOI: 10.1186/1477-7525-3-81] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
300 Yoon YH, Yi HY, Thomson PC. Alcohol-related and viral hepatitis C-related cirrhosis mortality among Hispanic subgroups in the United States, 2000-2004. Alcohol Clin Exp Res 2011;35:240-9. [PMID: 21121934 DOI: 10.1111/j.1530-0277.2010.01340.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
301 Baranoski AS, Cotton D, Heeren T, Nunes D, Kubiak RW, Horsburgh CR Jr. Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm(3) Is More Pronounced Among Women Than Men. Open Forum Infect Dis 2016;3:ofv214. [PMID: 26955643 DOI: 10.1093/ofid/ofv214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
302 Liebe R, Hall RA, Williams RW, Dooley S, Lammert F. Systems genetics of hepatocellular damage in vivo and in vitro: identification of a critical network on chromosome 11 in mouse. Physiol Genomics 2013;45:931-9. [PMID: 23943854 DOI: 10.1152/physiolgenomics.00078.2013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
303 Kanwal S, Mahmood T. Occurrence of genetic modifications in core, 5'UTR and NS5b of HCV associated with viral response to treatment. Virol J 2014;11:171. [PMID: 25270660 DOI: 10.1186/1743-422X-11-171] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
304 Adinolfi LE, Utili R, Andreana A, Tripodi MF, Marracino M, Gambardella M, Giordano M, Rugg-iero G. Serum HCV RNA levels correlate with his-tological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci. 2001;46:1677-1683. [PMID: 11508667 DOI: 10.1023/A:1010697319589] [Cited by in Crossref: 59] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
305 Liu Z, Zhao F, He JJ. Hepatitis C virus (HCV) interaction with astrocytes: nonproductive infection and induction of IL-18. J Neurovirol 2014;20:278-93. [PMID: 24671718 DOI: 10.1007/s13365-014-0245-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
306 Medrano LM, Berenguer J, Jiménez-Sousa MA, Aldámiz-Echevarria T, Tejerina F, Diez C, Vigón L, Fernández-Rodríguez A, Resino S. ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients. Sci Rep 2017;7:12918. [PMID: 29018269 DOI: 10.1038/s41598-017-12885-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
307 Tag-Adeen M, Sabra AM, Akazawa Y, Ohnita K, Nakao K. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement. Hepat Med. 2017;9:45-53. [PMID: 29062242 DOI: 10.2147/hmer.s142600] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
308 Pol S, Vallet-Pichard A, Hermine O. Extrahepatic cancers and chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2018;15:283-290. [PMID: 29339810 DOI: 10.1038/nrgastro.2017.172] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
309 Vigani AG, Pavan MH, Tozzo R, Gonçales ES, Feltrin A, Fais VC, Lazarini MS, Gonçales NS, Gonçales FL Jr. Comparative study of patients with chronic hepatitis C virus infection due to genotypes 1 and 3 referred for treatment in southeast Brazil. BMC Infect Dis 2008;8:164. [PMID: 19055835 DOI: 10.1186/1471-2334-8-164] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
310 Proeschold-Bell RJ, Patkar AA, Naggie S, Coward L, Mannelli P, Yao J, Bixby P, Muir AJ. An integrated alcohol abuse and medical treatment model for patients with hepatitis C. Dig Dis Sci. 2012;57:1083-1091. [PMID: 22134784 DOI: 10.1007/s10620-011-1976-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
311 Wan S, Huang C, Wang A, Zhu X. Ursolic acid improves the bacterial community mapping of the intestinal tract in liver fibrosis mice. PeerJ 2020;8:e9050. [PMID: 32355580 DOI: 10.7717/peerj.9050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
312 Tieu HV, Laeyendecker O, Nandi V, Rose R, Fernandez R, Lynch B, Hoover DR, Frye V, Koblin BA. Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City. PLoS One 2018;13:e0200269. [PMID: 30020960 DOI: 10.1371/journal.pone.0200269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
313 Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM; HALT-C Trial Group. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology 2011;141:900-908.e1-2. [PMID: 21699796 DOI: 10.1053/j.gastro.2011.06.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
314 Mücke MM, Mücke VT, Peiffer KH, Sarrazin C, Zeuzem S, Berger A, Vermehren J. Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study. Open Forum Infect Dis 2019;6:ofy340. [PMID: 30648130 DOI: 10.1093/ofid/ofy340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
315 Zhang D, Guo Z, Zhang P, Li Y, Su X, You L, Gao M, Liu C, Wu H, Zhang X. Simplified quantification method for in vivo SPECT/CT imaging of asialoglycoprotein receptor with (99m)Tc-p(VLA-co-VNI) to assess and stage hepatic fibrosis in mice. Sci Rep. 2016;6:25377. [PMID: 27150943 DOI: 10.1038/srep25377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
316 Dusheiko G, Barnes E, Webster G, Whalley S. The science, economics, and effectiveness of combination therapy for hepatitis C. Gut 2000;47:159-61. [PMID: 10896900 DOI: 10.1136/gut.47.2.159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
317 Kornek M, Lynch M, Mehta SH, Lai M, Exley M, Afdhal NH, Schuppan D. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology 2012;143:448-58. [PMID: 22537612 DOI: 10.1053/j.gastro.2012.04.031] [Cited by in Crossref: 117] [Cited by in F6Publishing: 112] [Article Influence: 11.7] [Reference Citation Analysis]
318 Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, Kleiner DE, Ghany MG, Alter HJ. A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis 2012;206:654-61. [PMID: 22740714 DOI: 10.1093/infdis/jis410] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
319 López-Menchero C, Alvarez M, Fernández P, Guzmán M, Ortiz-de-Salazar MI, Arbona C. Evolution of the residual risk of HBV, HCV and HIV transmission through blood transfusion in the Region of Valencia, Spain, during a 15-year period (2003-2017). Blood Transfus 2019;17:418-27. [PMID: 31403928 DOI: 10.2450/2019.0058-19] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
320 Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008;48:920-30. [PMID: 18613151 DOI: 10.1002/hep.22351] [Cited by in Crossref: 207] [Cited by in F6Publishing: 192] [Article Influence: 14.8] [Reference Citation Analysis]
321 Kamal S, Abdelhakam S, Ghoraba D, Mohsen MA, Salam AA, Hassan H, Nabeigh L. The Course of Hepatitis C Infection and Response to Anti-viral Therapy in Patients with Thalassemia major and Hepatitis C Infection: A Longitudinal, Prospective Study. Mediterr J Hematol Infect Dis 2019;11:e2019060. [PMID: 31700585 DOI: 10.4084/MJHID.2019.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
322 Anand BS, Velez M. Assessment of correlation between serum titers of hepatitis c virus and severity of liver disease. World J Gastroenterol 2004; 10(16): 2409-2411 [PMID: 15285030 DOI: 10.3748/wjg.v10.i16.2409] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
323 Bouayad A, Laamiri FZ, Elmoumou L, Rezzouk B, Hadef R. Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C. Pan Afr Med J 2021;39:32. [PMID: 34422155 DOI: 10.11604/pamj.2021.39.32.21235] [Reference Citation Analysis]
324 Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut. 2002;51:248-252. [PMID: 12117889 DOI: 10.1136/gut.51.2.248] [Cited by in Crossref: 229] [Cited by in F6Publishing: 213] [Article Influence: 11.5] [Reference Citation Analysis]
325 Chen Yi Mei SLG, Thompson AJ, Christensen B, Cunningham G, McDonald L, Bell S, Iser D, Nguyen T, Desmond PV. Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection. PLoS One 2017;12:e0185609. [PMID: 29065124 DOI: 10.1371/journal.pone.0185609] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
326 Jang H, Ryoo SR, Kim YK, Yoon S, Kim H, Han SW, Choi BS, Kim DE, Min DH. Discovery of Hepatitis C Virus NS3 Helicase Inhibitors by a Multiplexed, High-Throughput Helicase Activity Assay Based on Graphene Oxide. Angew Chem Weinheim Bergstr Ger 2013;125:2396-400. [PMID: 32313317 DOI: 10.1002/ange.201209222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
327 Queiroz DM, Rocha AM, Rocha GA, Cinque SM, Oliveira AG, Godoy A, Tanno H. Association between Helicobacter pylori infection and cirrhosis in patients with chronic hepatitis C virus. Dig Dis Sci 2006;51:370-3. [PMID: 16534683 DOI: 10.1007/s10620-006-3150-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
328 Lazaro R, Wu R, Lee S, Zhu NL, Chen CL, French SW, Xu J, Machida K, Tsukamoto H. Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology. 2015;61:129-140. [PMID: 25132354 DOI: 10.1002/hep.27383] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 9.6] [Reference Citation Analysis]
329 Serejo F, Costa A, Oliveira AG, Ramalho F, Batista A, De Moura MC. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III. Dig Dis Sci. 2001;46:1684-1689. [PMID: 11508668 DOI: 10.1023/a:1010649403659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
330 Schwarzinger M, Dewedar S, Rekacewicz C, Elaziz KMA, Fontanet A, Carrat F, Mohamed MK. Chronic hepatitis C virus infection: Does it really impact health-related quality of life? A study in rural Egypt. Hepatology 2004;40:1434-41. [DOI: 10.1002/hep.20468] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
331 Merani S, Petrovic D, James I, Chopra A, Cooper D, Freitas E, Rauch A, di Iulio J, John M, Lucas M. Effect of immune pressure on hepatitis C virus evolution: insights from a single-source outbreak. Hepatology. 2011;53:396-405. [PMID: 21246583 DOI: 10.1002/hep.24076] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
332 Villa E, Vukotic R, Cammà C, Petta S, Di Leo A, Gitto S, Turola E, Karampatou A, Losi L, Bernabucci V. Reproductive status is associated with the severity of fibrosis in women with hepatitis C. PLoS One. 2012;7:e44624. [PMID: 22970270 DOI: 10.1371/journal.pone.0044624] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
333 Stoller EP, Hund AJ, Webster NJ, Blixen CE, Perzynski AT, McCormick RA, Kanuch SW, Dawson NV. Alcohol consumption within the context of hepatitis C: a qualitative study of non-problematic drinkers. Alcohol Alcohol. 2006;41:546-552. [PMID: 16855001 DOI: 10.1093/alcalc/agl055] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
334 Eyster ME, Kong L, Li M, Schreibman IR. Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort. Am J Hematol 2016;91:E335-40. [PMID: 27214557 DOI: 10.1002/ajh.24427] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
335 Liang J, Song X, Xiao Z, Chen H, Shi C, Luo L. Using IVIM-MRI and R2⁎ Mapping to Differentiate Early Stage Liver Fibrosis in a Rat Model of Radiation-Induced Liver Fibrosis. Biomed Res Int 2018;2018:4673814. [PMID: 30627558 DOI: 10.1155/2018/4673814] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
336 Falade-Nwulia O, Thio CL. Liver disease, HIV and aging. Sex Health 2011;8:512-20. [PMID: 22127037 DOI: 10.1071/SH10163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
337 Stoller EP, Webster NJ, Blixen CE, McCormick RA, Perzynski AT, Kanuch SW, Dawson NV. Lay management of chronic disease: a qualitative study of living with hepatitis C infection. Am J Health Behav 2009;33:376-90. [PMID: 19182983 DOI: 10.5993/ajhb.33.4.4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
338 Buettner N, Thimme R. Sexual dimorphism in hepatitis B and C and hepatocellular carcinoma. Semin Immunopathol 2019;41:203-11. [PMID: 30498927 DOI: 10.1007/s00281-018-0727-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
339 Jordan AE, Perlman DC, Cleland CM, Wyka K, Schackman BR, Nash D. Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. J Clin Virol 2020;124:104285. [PMID: 32007842 DOI: 10.1016/j.jcv.2020.104285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
340 Hu Z, Li Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status. Dig Dis Sci 2014;59:3062-72. [PMID: 25008426 DOI: 10.1007/s10620-014-3266-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
341 Ito Y, Yamamoto N, Nakata R, Kato Y, Iori M, Sakai K, Takemura T, Tateishi R, Yoshida H, Kawabe T, Omata M. Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World J Gastroenterol 2005;11:7218-21. [PMID: 16437676 DOI: 10.3748/wjg.v11.i45.7218] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
342 Aithal GP, Guha N, Fallowfield J, Castera L, Jackson AP. Biomarkers in liver disease: emerging methods and potential applications. Int J Hepatol 2012;2012:437508. [PMID: 23209913 DOI: 10.1155/2012/437508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
343 Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011;3:69-80. [PMID: 24367223 DOI: 10.2147/hmer.s9051] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
344 Manos MM, Ho CK, Murphy RC, Shvachko VA. Physical, social, and psychological consequences of treatment for hepatitis C: a community-based evaluation of patient-reported outcomes. Patient. 2013;6:23-34. [PMID: 23420134 DOI: 10.1007/s40271-013-0005-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
345 Imran M, Manzoor S, Ashraf J, Khalid M, Tariq M, Khaliq HM, Azam S. Role of viral and host factors in interferon based therapy of hepatitis C virus infection. Virol J. 2013;10:299. [PMID: 24079723 DOI: 10.1186/1743-422x-10-299] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
346 Eskander EF, Abd-Rabou AA, Yahya SM, El Sherbini A, Mohamed MS, Shaker OG. "P53 codon 72 single base substitution in viral hepatitis C and hepatocarcinoma incidences". Indian J Clin Biochem 2014;29:3-7. [PMID: 24478542 DOI: 10.1007/s12291-013-0317-0] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
347 Matsumura H, Nirei K, Nakamura H, Higuchi T, Arakawa Y, Ogawa M, Tanaka N, Moriyama M. Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors. World J Gastroenterol 2013; 19(30): 4887-4896 [PMID: 23946593 DOI: 10.3748/wjg.v19.i30.4887] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
348 Li CZ, Kato N, Chang JH, Muroyama R, Shao RX, Dharel N, Sermsathanasawadi R, Kawabe T, Omata M. Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. Liver Int. 2009;29:1413-1421. [PMID: 19515215 DOI: 10.1111/j.1478-3231.2009.02061.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
349 Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F, Sansonno D. Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study. Medicine (Baltimore). 2013;92:245-256. [PMID: 23982056 DOI: 10.1097/md.0b013e31829d2abc] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
350 Ray Saraswati L, Sarna A, Sebastian MP, Sharma V, Madan I, Thior I, Pulerwitz J, Tun W. HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India. BMC Public Health 2015;15:726. [PMID: 26223866 DOI: 10.1186/s12889-015-2003-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
351 Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P, Spiegel B. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci 2011;56:3024-31. [PMID: 21717127 DOI: 10.1007/s10620-011-1802-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
352 Flohr TR, Bonatti H, Hranjec T, Keith DS, Lobo PI, Kumer SC, Schmitt TM, Sawyer RG, Pruett TL, Roberts JP. Elderly recipients of hepatitis C positive renal allografts can quickly develop liver disease. J Surg Res. 2012;176:629-638. [PMID: 22316669 DOI: 10.1016/j.jss.2011.10.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
353 Hoare M, Gelson WT, Das A, Fletcher JM, Davies SE, Curran MD, Vowler SL, Maini MK, Akbar AN, Alexander GJ. CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. J Hepatol 2010;53:252-60. [PMID: 20462651 DOI: 10.1016/j.jhep.2010.03.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
354 Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-8. [PMID: 15710992 DOI: 10.1136/gut.2004.048124] [Cited by in Crossref: 173] [Cited by in F6Publishing: 162] [Article Influence: 10.2] [Reference Citation Analysis]
355 Curto TM, Lagier RJ, Lok AS, Everhart JE, Rowland CM, Sninsky JJ. Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics. 2011;21:851-860. [PMID: 21946897 DOI: 10.1097/fpc.0b013e32834c3e74] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
356 Sagnelli C, Uberti-Foppa C, Hasson H, Bellini G, Minichini C, Salpietro S, Messina E, Barbanotti D, Merli M, Punzo F, Coppola N, Lazzarin A, Sagnelli E, Rossi F. Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients. PLoS One 2017;12:e0181890. [PMID: 28759568 DOI: 10.1371/journal.pone.0181890] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
357 Huang KC, Chuang MH, Lin ZS, Lin YC, Chen CH, Chang CL, Huang PC, Syu WS, Chiou TW, Hong ZH, Tsai YC, Harn HJ, Lin PC, Lin SZ. Transplantation with GXHPC1 for Liver Cirrhosis: Phase 1 Trial. Cell Transplant 2019;28:100S-11S. [PMID: 31722556 DOI: 10.1177/0963689719884885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
358 Chaillon A, Rand EB, Reau N, Martin NK. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis 2019;69:1888-95. [PMID: 30689769 DOI: 10.1093/cid/ciz063] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
359 Wen X, Yao M, Lu Y, Chen J, Zhou J, Chen X, Zhang Y, Lu W, Qian X, Zhao J, Zhang L, Ding S, Lu F. Integration of Prealbumin into Child-Pugh Classification Improves Prognosis Predicting Accuracy in HCC Patients Considering Curative Surgery. J Clin Transl Hepatol. 2018;6:377-384. [PMID: 30637214 DOI: 10.14218/jcth.2018.00004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
360 El-mezayen HA, Darwish H. Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients. Tumour Biol 2014;35:6501-9. [PMID: 24687551 DOI: 10.1007/s13277-014-1858-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
361 Liu J, Sun D, Liu J, Xu H, Liu Y, Li Y, Diao L, Wang X, Wang D, Tian L, Zhang H, Liu Z, Ren W, He F, Li D, Guo S. FibroAtlas: A Database for the Exploration of Fibrotic Diseases and Their Genes. Cardiol Res Pract 2019;2019:4237285. [PMID: 32082621 DOI: 10.1155/2019/4237285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
362 Anand BS, Thornby J. Alcohol has no effect on hepatitis C virus replication: a meta-analysis. Gut 2005;54:1468-72. [PMID: 16162952 DOI: 10.1136/gut.2004.056697] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
363 Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int. 2013;2013:564645. [PMID: 23956991 DOI: 10.1155/2013/564645] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
364 Cramp ME, Rosenberg WM, Ryder SD, Blach S, Parkes J. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol 2014;14:137. [PMID: 25100159 DOI: 10.1186/1471-230X-14-137] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
365 Pandita H, Mezey E, Ganapathy-Kanniappan S. Augmented Liver Uptake of the Membrane Voltage Sensor Tetraphenylphosphonium Distinguishes Early Fibrosis in a Mouse Model. Front Physiol 2021;12:676722. [PMID: 34759830 DOI: 10.3389/fphys.2021.676722] [Reference Citation Analysis]
366 Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM. Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:713-728. [PMID: 24019151 DOI: 10.1038/nrgastro.2013.163] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
367 Thursz M. Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection. Gut 2007;56:613-4. [PMID: 17440181 DOI: 10.1136/gut.2006.113076] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
368 Carty PG, McCarthy M, O'Neill SM, De Gascun CF, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy. Rev Med Virol 2021;:e2320. [PMID: 34957630 DOI: 10.1002/rmv.2320] [Reference Citation Analysis]
369 Patel S, Jinjuvadia R, Patel R, Liangpunsakul S. Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients: A Systemic Review and Meta-Analysis. J Clin Gastroenterol 2016;50:80-4. [PMID: 26302498 DOI: 10.1097/MCG.0000000000000400] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
370 Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, Boscarino JA, Henkle EM, Gordon SC. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis. 2013;57:240-246. [PMID: 23592832 DOI: 10.1093/cid/cit245] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 9.9] [Reference Citation Analysis]
371 Staten NR, Welsh EA, Sidik K, McDonald SA, Dufield DR, Maqsodi B, Ma Y, McMaster GK, Mathews RW, Arch RH, Masferrer JL, Souberbielle BE. Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis. Fibrogenesis Tissue Repair 2012;5:21. [PMID: 23270325 DOI: 10.1186/1755-1536-5-21] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
372 Kucherenko AM, Moroz LV, Bevz TI, Bulavenko VI, Antypkin YG, Berezenko VS, Dyba MB, Pampukha VM, Gorodna OV, Livshits LA. Investigation of rs11536889 + 3725G/C Polymorphism of the TLR4 Gene in Patients with Autoimmune and Chronic Viral Hepatitis C. Cytol Genet 2019;53:300-6. [DOI: 10.3103/s0095452719040078] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
373 Schackman BR, Leff JA, Barter DM, DiLorenzo MA, Feaster DJ, Metsch LR, Freedberg KA, Linas BP. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction 2015;110:129-43. [PMID: 25291977 DOI: 10.1111/add.12754] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
374 Takeda T, Yasuda T, Nakayama Y, Nakaya M, Kimura M, Yamashita M, Sawada A, Abo K, Takeda S, Sakaguchi H, Shiomi S, Asai H, Seki S. Usefulness of noninvasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C. World J Gastroenterol 2006; 12(48): 7768-7773 [PMID: 17203518 DOI: 10.3748/wjg.v12.i48.7768] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
375 Guzman G, Chennuri R, Voros A, Boumendjel R, Locante A, Patel R, Valyi-nagy T. Nucleometric Study of Anisonucleosis, Diabetes and Oxidative Damage in Liver Biopsies of Orthotopic Liver Transplant Recipients with Chronic Hepatitis C Virus Infection. Pathol Oncol Res 2011;17:191-9. [DOI: 10.1007/s12253-010-9296-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
376 Rasi G, Serafino A, Bellis L, Lonardo MT, Andreola F, Zonfrillo M, Vennarecci G, Pierimarchi P, Vallebona PS, Ettorre GM, Santoro E, Puoti C. Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2007; 13(37): 4986-4995 [PMID: 17854142 DOI: 10.3748/wjg.v13.i37.4986] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
377 Askar E, Ramadori G, Mihm S. Endotoxin receptor CD14 gene variants and histological features in chronic HCV infection. World J Gastroenterol 2009; 15(31): 3884-3890 [PMID: 19701968 DOI: 10.3748/wjg.15.3884] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
378 Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-218. [PMID: 15690074 DOI: 10.1172/JCI200524282.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
379 Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology. 2002;36:S220-S225. [PMID: 12407597 DOI: 10.1002/hep.1840360728] [Cited by in Crossref: 71] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
380 Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B, Romagnani P, Milani S, Ginés P. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol. 2006;169:2042-2053. [PMID: 17148667 DOI: 10.2353/ajpath.2006.060081] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 7.1] [Reference Citation Analysis]
381 Mackawy AM, Badawy ME, Megahed OAEY. Angiotensin converting enzyme (ACE D/I) polymorphism and its relation to liver fibrosis progression in Egyptian patients with chronic hepatitis C virus infection. Egyptian Journal of Medical Human Genetics 2012;13:291-9. [DOI: 10.1016/j.ejmhg.2012.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
382 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14(27): 4300-4308 [PMID: 18666317 DOI: 10.3748/wjg.14.4300] [Cited by in CrossRef: 408] [Cited by in F6Publishing: 377] [Article Influence: 29.1] [Reference Citation Analysis]
383 Hagström H. Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much? Curr Hepatol Rep 2017;16:152-7. [PMID: 28706775 DOI: 10.1007/s11901-017-0343-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
384 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
385 Nakano I, Fukuda Y, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Kumada T, Nakano S. Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype. Gut 2001;49:263-7. [PMID: 11454804 DOI: 10.1136/gut.49.2.263] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
386 Grizzi F, Di Caro G, Laghi L, Hermonat P, Mazzola P, Nguyen DD, Radhi S, Figueroa JA, Cobos E, Annoni G. Mast cells and the liver aging process. Immun Ageing. 2013;10:9. [PMID: 23496863 DOI: 10.1186/1742-4933-10-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
387 Colombo D, Zullo A, Simoni L, Zagni E; SURF Study Group. The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): a post-hoc between-sex analysis. BMC Nephrol 2019;20:475. [PMID: 31870321 DOI: 10.1186/s12882-019-1656-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
388 Delire B, Lebrun V, Selvais C, Henriet P, Bertrand A, Horsmans Y, Leclercq IA. Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling. Aging (Albany NY). 2016;9:98-113. [PMID: 27941216 DOI: 10.18632/aging.101124] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
389 Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in Liver Cirrhosis. Int J Mol Sci 2017;18:E1392. [PMID: 28661458 DOI: 10.3390/ijms18071392] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
390 Cengiz M, Ozenirler S, Yılmaz G. Estrogen receptor alpha expression and liver fibrosis in chronic hepatitis C virus genotype 1b: a clinicopathological study. Hepat Mon 2014;14:e21885. [PMID: 25368658 DOI: 10.5812/hepatmon.21885] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
391 An P, Wei LL, Zhao S, Sverdlov DY, Vaid KA, Miyamoto M, Kuramitsu K, Lai M, Popov YV. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis. Nat Commun 2020;11:2362. [PMID: 32398673 DOI: 10.1038/s41467-020-16092-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
392 Montes-Cano M, García-Lozano J, Aguilar-Reina J, Romero-Gómez M, Barroso N, Núñez-Roldán A, González-Escribano M. CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population. World J Gastroenterol 2007; 13(15): 2187-2192 [PMID: 17465499 DOI: 10.3748/wjg.v13.i15.2187] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
393 Mölleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009;49:1257-1266. [PMID: 19177598 DOI: 10.1002/hep.22764] [Cited by in Crossref: 104] [Cited by in F6Publishing: 103] [Article Influence: 8.0] [Reference Citation Analysis]
394 Leggio L, Lee MR. Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. Am J Med. 2017;130:124-134. [PMID: 27984008 DOI: 10.1016/j.amjmed.2016.10.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
395 Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-218. [PMID: 15690074 DOI: 10.1172/jci24282] [Cited by in Crossref: 3033] [Cited by in F6Publishing: 1550] [Article Influence: 178.4] [Reference Citation Analysis]
396 Yi X, Long L, Yang C, Lu Y, Cheng M. Maotai ameliorates diethylnitrosamine-initiated hepatocellular carcinoma formation in mice. PLoS One 2014;9:e93599. [PMID: 24690765 DOI: 10.1371/journal.pone.0093599] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
397 Pence BW, Thielman NM, Whetten K, Ostermann J, Kumar V, Mugavero MJ. Coping strategies and patterns of alcohol and drug use among HIV-infected patients in the United States Southeast. AIDS Patient Care STDS 2008;22:869-77. [PMID: 19025481 DOI: 10.1089/apc.2008.0022] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
398 Sato M, Kondo M, Tateishi R, Fujiwara N, Kato N, Yoshida H, Taguri M, Koike K. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One 2014;9:e91822. [PMID: 24637774 DOI: 10.1371/journal.pone.0091822] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
399 Hoare M, Shankar A, Shah M, Rushbrook S, Gelson W, Davies S, Akbar A, Alexander GJ. γ-H2AX+CD8+ T lymphocytes cannot respond to IFN-α, IL-2 or IL-6 in chronic hepatitis C virus infection. J Hepatol 2013;58:868-74. [PMID: 23257612 DOI: 10.1016/j.jhep.2012.12.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
400 Moreno-Cubero E, Subirá D, Sanz-de-Villalobos E, Parra-Cid T, Madejón A, Miquel J, Olveira A, González-Praetorius A, García-Samaniego J, Larrubia JR. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity. J Virol 2018;92:e01443-17. [PMID: 29093082 DOI: 10.1128/JVI.01443-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
401 Minuk GY, Uhanova J, Kaita KD. The prevalence of intrinsic host risk factors associated with progressive disease in patients with chronic hepatitis C viral infections. Can J Public Health 2000;91:171-5. [PMID: 10927842 [PMID: 10927842 DOI: 10.1007/bf03404265] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
402 Kalita K, Filipczak K, Bieńkiewicz M, Deroń W, Deroń Z, Piekarska A, Płachcińska A, Kuśmierek J. Diagnostic value of optimised real-time sonoelastography in the assessment of liver fibrosis in chronic hepatitis B and C. Prz Gastroenterol 2017;12:28-33. [PMID: 28337233 DOI: 10.5114/pg.2016.61475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
403 Stroffolini T, Sagnelli E, Sagnelli C, Morisco F, Babudieri S, Furlan C, Pirisi M, Russello M, Smedile A, Pisaturo M, Almasio PL. Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy. Can J Gastroenterol Hepatol. 2018;2018:9151820. [PMID: 30345260 DOI: 10.1155/2018/9151820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
404 Coppola N, Alessio L, Onorato L, Sagnelli C, Macera M, Sagnelli E, Pisaturo M. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty 2019;8:17. [PMID: 30871599 DOI: 10.1186/s40249-019-0528-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
405 Shiffman ML. Living donor liver transplantation in patients with chronic hepatitis C: timing is everything. Liver Transpl 2003;9:1036-9. [PMID: 14526397 DOI: 10.1053/jlts.2003.50262] [Reference Citation Analysis]
406 Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics. 2006;24:661-672. [PMID: 16802842 DOI: 10.2165/00019053-200624070-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
407 Linas BP, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. Open Forum Infect Dis 2017;4:ofw266. [PMID: 28480259 DOI: 10.1093/ofid/ofw266] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
408 Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology. 2012;143:1244-1252.e1-12. [PMID: 22841784 DOI: 10.1053/j.gastro.2012.07.097] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 10.8] [Reference Citation Analysis]
409 Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol 2008;22:381-7. [PMID: 18414713 DOI: 10.1155/2008/173153] [Cited by in Crossref: 26] [Cited by in F6Publishing: 39] [Article Influence: 1.9] [Reference Citation Analysis]
410 Gourtsoyianni S, Santinha J, Matos C, Papanikolaou N. Diffusion-weighted imaging and texture analysis: current role for diffuse liver disease. Abdom Radiol (NY) 2020;45:3523-31. [PMID: 33064169 DOI: 10.1007/s00261-020-02772-4] [Reference Citation Analysis]
411 Kubota J, Ikeda F, Terada R, Kobashi H, Fujioka S, Okamoto R, Baba S, Morimoto Y, Ando M, Makino Y, Taniguchi H, Yasunaka T, Miyake Y, Iwasaki Y, Yamamoto K. Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. J Gastroenterol 2009;44:1000-6. [PMID: 19562250 DOI: 10.1007/s00535-009-0090-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
412 Akpo EI, Sbarigia U, Wan G, Kleintjens J. Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. Drugs R D 2015;15:335-49. [PMID: 26416653 DOI: 10.1007/s40268-015-0109-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
413 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1056/s0140-6736(08)60383-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
414 Farmand S, Wirth S, Löffler H, Woltering T, Kenzel S, Lainka E, Henneke P. Spontaneous clearance of hepatitis C virus in vertically infected children. Eur J Pediatr. 2012;171:253-258. [PMID: 21735055 DOI: 10.1007/s00431-011-1517-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
415 Woods B, Faria R, Griffin S. Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right? Pharmacoeconomics 2016;34:427-33. [PMID: 26714687 DOI: 10.1007/s40273-015-0369-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
416 Kim IH, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin Gastroenterol. 2015;31:184-191. [PMID: 25850346 DOI: 10.1097/mog.0000000000000176] [Cited by in Crossref: 138] [Cited by in F6Publishing: 70] [Article Influence: 23.0] [Reference Citation Analysis]
417 Yen YH, Wang JC, Hung CH, Lu SN, Wang JH, Hu TH, Kee KM, Hsiao CC, Lee CM. Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin. J Formos Med Assoc 2015;114:652-8. [PMID: 23810703 DOI: 10.1016/j.jfma.2013.04.013] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
418 Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015; 7(28): 2792-2810 [PMID: 26668691 DOI: 10.4254/wjh.v7.i28.2792] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
419 Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int. 2009;29 Suppl 1:89-99. [PMID: 19207971 DOI: 10.1111/j.1478-3231.2008.01927.x] [Cited by in Crossref: 161] [Cited by in F6Publishing: 151] [Article Influence: 12.4] [Reference Citation Analysis]
420 Niu X, Wang X, Niu B, Meng Y, He H, Wang Y, Li G. Costunolide Loaded in pH-Responsive Mesoporous Silica Nanoparticles for Increased Stability and an Enhanced Anti-Fibrotic Effect. Pharmaceuticals (Basel) 2021;14:951. [PMID: 34681175 DOI: 10.3390/ph14100951] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
421 Burza MA, Molinaro A, Attilia ML, Rotondo C, Attilia F, Ceccanti M, Ferri F, Maldarelli F, Maffongelli A, De Santis A. PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis. Liver Int. 2014;34:514-520. [PMID: 24102786 DOI: 10.1111/liv.12310] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
422 Núñez O, Fernández-Martínez A, Majano PL, Apolinario A, Gómez-Gonzalo M, Benedicto I, López-Cabrera M, Boscá L, Clemente G, García-Monzón C, Martín-Sanz P. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004;53:1665-72. [PMID: 15479690 DOI: 10.1136/gut.2003.038364] [Cited by in Crossref: 113] [Cited by in F6Publishing: 112] [Article Influence: 6.3] [Reference Citation Analysis]
423 Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels. Hepat Mon 2012;12:77-84. [PMID: 22509183 DOI: 10.5812/hepatmon.829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
424 Lagging LM, Garcia CE, Westin J, Wejstål R, Norkrans G, Dhillon AP, Lindh M. Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. J Clin Microbiol 2002;40:4224-9. [PMID: 12409402 DOI: 10.1128/JCM.40.11.4224-4229.2002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
425 Walewska-Zielecka B, Religioni U, Juszczyk G, Wawrzyniak ZM, Czerw A, Soszyński P, Fronczak A. Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014. Euro Surveill 2017;22:30441. [PMID: 28106526 DOI: 10.2807/1560-7917.ES.2017.22.2.30441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
426 Allen AM, Heimbach JK, Larson JJ, Mara KC, Kim WR, Kamath PS, Therneau TM. Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. Transplantation 2018;102:1710-6. [PMID: 29620614 DOI: 10.1097/TP.0000000000002196] [Cited by in Crossref: 41] [Cited by in F6Publishing: 10] [Article Influence: 13.7] [Reference Citation Analysis]
427 Tsochatzis EA, Crossan C, Longworth L, Gurusamy K, Rodriguez-Peralvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V, Noel-Storr A. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology. 2014;60:832-843. [PMID: 25043847 DOI: 10.1002/hep.27296] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
428 Colagreco JP, Bailey DE, Fitzpatrick JJ, Musil CM, Afdhal NH, Lai M. Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic hepatitis C. J Viral Hepat 2014;21:727-33. [PMID: 25280230 DOI: 10.1111/jvh.12207] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
429 Lin TJ, Liao LY, Lin SY, Lin CL, Chang TA. Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C. World J Gastroenterol 2006; 12(30): 4897-4901 [PMID: 16937477 DOI: 10.3748/wjg.v12.i30.4897] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
430 Liu Z, He JJ. Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors. J Virol 2013;87:8545-58. [PMID: 23720720 DOI: 10.1128/JVI.01062-13] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
431 Mukamal KJ, Clowry CM, Murray MM, Hendriks HF, Rimm EB, Sink KM, Adebamowo CA, Dragsted LO, Lapinski PS, Lazo M, Krystal JH. Moderate Alcohol Consumption and Chronic Disease: The Case for a Long-Term Trial. Alcohol Clin Exp Res 2016;40:2283-91. [PMID: 27688006 DOI: 10.1111/acer.13231] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
432 Verma S, Goldin RD, Main J. Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis? BMC Res Notes 2008;1:46. [PMID: 18710499 DOI: 10.1186/1756-0500-1-46] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
433 Grzegorzewska AE, Świderska MK, Mostowska A, Jagodziński PP. Circulating Interferon-λ3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients. Biomed Res Int 2017;2017:3713025. [PMID: 29226133 DOI: 10.1155/2017/3713025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
434 Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut. 2003;52:404-409. [PMID: 12584224 DOI: 10.1136/gut.52.3.404] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 4.0] [Reference Citation Analysis]
435 Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011;3:69-80. [PMID: 24367223 DOI: 10.2147/hmer.s905] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
436 Mercer DF. Animal models for studying hepatitis C and alcohol effects on liver. World J Gastroenterol 2011; 17(20): 2515-2519 [PMID: 21633656 DOI: 10.3748/wjg.v17.i20.2515] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
437 Tobler LH, Bahrami SH, Kaidarova Z, Pitina L, Winkelman VK, Vanderpool SK, Guiltinan AM, Cooper S, Busch MP, Murphy EL. A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME). Transfusion 2010;50:1513-23. [PMID: 20345567 DOI: 10.1111/j.1537-2995.2010.02634.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
438 El Awady MK, Bader El Din NG, Abdel Aziz Riad M, Omran MH, Abdelhafez TH, Elbaz TM, Hunter SS, Dawood RM, Abdel Aziz AO. Predictors of disease recurrence post living donor liver transplantation in end stage chronic HCV patients. Dis Markers 2014;2014:202548. [PMID: 24695489 DOI: 10.1155/2014/202548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
439 McCaughan GW. Asian perspectives on viral hepatitis: hepatitis C virus infection. J Gastroenterol Hepatol 2000;15 Suppl:G90-3. [PMID: 11101001 DOI: 10.1046/j.1440-1746.2000.02273.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
440 Gonzales CA, Bacchetti P, Khalili M. Impact of gender and menopausal status on metabolic parameters in chronic hepatitis C infection. J Viral Hepat 2016;23:232-9. [PMID: 26554398 DOI: 10.1111/jvh.12487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
441 Pietsch V, Deterding K, Attia D, Ringe KI, Heidrich B, Cornberg M, Gebel M, Manns MP, Wedemeyer H, Potthoff A. Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. United European Gastroenterol J 2018;6:1188-98. [PMID: 30288281 DOI: 10.1177/2050640618786067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
442 Boodram B, Hershow RC, Cotler SJ, Ouellet LJ. Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users. Drug Alcohol Depend 2011;119:166-71. [PMID: 21724339 DOI: 10.1016/j.drugalcdep.2011.06.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
443 Kjellin M, Wesslén T, Löfblad E, Lennerstrand J, Lannergård A. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Ups J Med Sci 2018;123:50-6. [PMID: 29536805 DOI: 10.1080/03009734.2018.1441928] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
444 Plebani JG, Tirado CF, Pettinati HM, Kampman KM, Volpicelli JR, Oslin DW. Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence. Addict Behav 2010;35:123-8. [PMID: 19783106 DOI: 10.1016/j.addbeh.2009.09.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
445 Cepeda JA, Thomas DL, Astemborski J, Sulkowski MS, Kirk GD, Mehta SH. Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study. Clin Infect Dis 2017;65:235-43. [PMID: 28329108 DOI: 10.1093/cid/cix207] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
446 Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S, Fumolo E, Bignulin S, Fontanini E, Cerutti A. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol. 2011;31:891-899. [PMID: 21647799 DOI: 10.1007/s10875-011-9547-1] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
447 Burness CB. Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C. Drugs 2014;74:1961-71. [PMID: 25331767 DOI: 10.1007/s40265-014-0312-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
448 Harrison-Findik DD. Gender-related variations in iron metabolism and liver diseases. World J Hepatol 2010; 2(8): 302-310 [PMID: 21161013 DOI: 10.4254/wjh.v2.i8.302] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
449 Parikh ND, Fu S, Rao H, Yang M, Li Y, Powell C, Wu E, Lin A, Xing B, Wei L, Lok ASF. Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA. Dig Dis Sci 2017;62:3243-53. [PMID: 28948495 DOI: 10.1007/s10620-017-4776-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
450 Zakaria S, Youssef M, Moussa M, Akl M, El-Ahwany E, El-Raziky M, Mostafa O, Helmy AH, El-Hindawi A. Value of α-smooth muscle actin and glial fibrillary acidic protein in predicting early hepatic fibrosis in chronic hepatitis C virus infection. Arch Med Sci 2010;6:356-65. [PMID: 22371771 DOI: 10.5114/aoms.2010.14255] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
451 Wu YJ, Xu MY, Lu LG. Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C. J Clin Transl Hepatol 2014;2:222-7. [PMID: 26357628 DOI: 10.14218/JCTH.2014.00029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
452 Udompap P, Mannalithara A, Heo NY, Kim D, Kim WR. Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. J Hepatol. 2016;64:1027-1032. [PMID: 26809112 DOI: 10.1016/j.jhep.2016.01.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
453 Zaitoun AM, Al Mardini H, Awad S, Ukabam S, Makadisi S, Record CO. Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C. J Clin Pathol. 2001;54:461-465. [PMID: 11376020 DOI: 10.1136/jcp.54.6.461] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 2.9] [Reference Citation Analysis]
454 Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Lissandrin R, Filice G, Filice C, Above E, Barbarini G, Brunetti E, Calderon W, Di Gregorio M, Gulminetti R, Lanzarini P, Ludovisi S, Maiocchi L, Malfitano A, Michelone G, Minoli L, Mondelli M, Novati S, Patruno SF, Perretti A, Poma G, Sacchi P, Zanaboni D, Zaramella M. Performance of liver stiffness measurements by transient elastography in chronic hepatitis. World J Gastroenterol 2013; 19(1): 49-56 [PMID: 23326162 DOI: 10.3748/wjg.v19.i1.49] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
455 Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis C infection. Cochrane Database Syst Rev 2018;12:CD011644. [PMID: 30521693 DOI: 10.1002/14651858.CD011644.pub3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
456 Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, Balagopal A, Thomas DL. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013;158:658-666. [PMID: 23440167 DOI: 10.7326/0003-4819-158-9-201305070-00604] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 12.9] [Reference Citation Analysis]
457 Helmke S, Colmenero J, Everson GT. Noninvasive assessment of liver function. Curr Opin Gastroenterol. 2015;31:199-208. [PMID: 25714706 DOI: 10.1097/mog.0000000000000167] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
458 Cieśla A, Kuśmider M, Faron-Górecka A, Dziedzicka-Wasylewska M, Bociąga-Jasik M, Owczarek D, Ciećko-Michalska I, Cibor D, Mach T. Intrahepatic expression of genes related to metabotropic receptors in chronic hepatitis. World J Gastroenterol 2012; 18(31): 4156-4161 [PMID: 22919248 DOI: 10.3748/wjg.v18.i31.4156] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
459 Bahl G, Cruite I, Wolfson T, Gamst AC, Collins JM, Chavez AD, Barakat F, Hassanein T, Sirlin CB. Noninvasive classification of hepatic fibrosis based on texture parameters from double contrast-enhanced magnetic resonance images. J Magn Reson Imaging 2012;36:1154-61. [PMID: 22851409 DOI: 10.1002/jmri.23759] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
460 Grgurevic I, Puljiz Z, Brnic D, Bokun T, Heinzl R, Lukic A, Luksic B, Kujundzic M, Brkljacic B. Liver and spleen stiffness and their ratio assessed by real-time two dimensional-shear wave elastography in patients with liver fibrosis and cirrhosis due to chronic viral hepatitis. Eur Radiol. 2015;25:3214-3221. [PMID: 25903706 DOI: 10.1007/s00330-015-3728-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
461 Tao X, Wang N, Wang J, Fu Z, Gu Z, Zhang Y, Chen S, Wang L, Yu L. Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor. Antimicrob Agents Chemother 2019:AAC. [PMID: 31527036 DOI: 10.1128/AAC.01237-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
462 Boillot O, Dumortier J. Immunosuppression in HCV-positive liver transplant recipients: Pandora's box? Liver Transpl 2007;13:1500-2. [PMID: 17969204 DOI: 10.1002/lt.21224] [Reference Citation Analysis]
463 Féray C. Steroid and azathoprine maintenance as the best regimen during recurrent hepatitis C? Liver Transpl 2005;11:384-5. [PMID: 15776455 DOI: 10.1002/lt.20396] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
464 Zeremski M, Dimova RB, Pillardy J, de Jong YP, Jacobson IM, Talal AH. Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection. J Infect Dis 2016;214:1164-70. [PMID: 27485356 DOI: 10.1093/infdis/jiw332] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
465 Batey RG. Controversies in and challenges to our understanding of hepatitis C. World J Gastroenterol 2007; 13(31): 4168-4176 [PMID: 17696244 DOI: 10.3748/wjg.v13.i31.4168] [Reference Citation Analysis]
466 Akiyama MJ, Agyemang L, Arnsten JH, Heo M, Norton BL, Schackman BR, Linas BP, Litwin AH. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infect Dis 2018;18:74. [PMID: 29426304 DOI: 10.1186/s12879-018-2964-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
467 Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, Asad S, Shahid I, Sumrin A, Khaliq S. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol. 2011;11:44. [PMID: 21507271 DOI: 10.1186/1471-230x-11-44] [Cited by in Crossref: 51] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
468 Kim JH, Han KH, Lee KS, Park YN, Ahn SH, Chon CY, Moon YM. Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea. Yonsei Med J 2006;47:793-8. [PMID: 17191307 DOI: 10.3349/ymj.2006.47.6.793] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
469 Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis. 2008;12:713-726, xi. [PMID: 18625436 DOI: 10.1016/j.cld.2008.03.002] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.0] [Reference Citation Analysis]
470 Sanai FM, Alghamdi H, Alswat KA, Babatin MA, Ismail MH, Alhamoudi WK, Alalwan AM, Dahlan Y, Alghamdi AS, Alfaleh FZ, Aljumah AA, Altraif IH, Albeladi K, Batwa F, Alshumrani W, Belhadi D, Genestier V, Abdo AA. Greater prevalence of comorbidities with increasing age: Cross-sectional analysis of chronic hepatitis B patients in Saudi Arabia. Saudi J Gastroenterol 2019;25:194-200. [PMID: 30720002 DOI: 10.4103/sjg.SJG_447_18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
471 Boivin Z, Perez MF, Atuegwu NC, Anzueto A, Mortensen EM. Impact of Cirrhosis on Pneumonia-Related Outcomes in Hospitalized Older Veterans. Am J Med Sci 2019;357:296-301. [PMID: 30904044 DOI: 10.1016/j.amjms.2019.01.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
472 Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012;142:1324-1334.e3. [PMID: 22537439 DOI: 10.1053/j.gastro.2012.02.012] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
473 Oze T, Hiramatsu N, Kurashige N, Tsuda N, Yakushijin T, Kanto T, Takehara T, Kasahara A, Kato M, Yoshihara H. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. J Gastroenterol. 2006;41:862-872. [PMID: 17048050 DOI: 10.1007/s00535-006-1858-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
474 Lau-Corona D, Suvorov A, Waxman DJ. Feminization of Male Mouse Liver by Persistent Growth Hormone Stimulation: Activation of Sex-Biased Transcriptional Networks and Dynamic Changes in Chromatin States. Mol Cell Biol 2017;37:e00301-17. [PMID: 28694329 DOI: 10.1128/MCB.00301-17] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 7.4] [Reference Citation Analysis]
475 Zeuzem S. Treatment Options in Hepatitis C. Dtsch Arztebl Int 2017;114:11-21. [PMID: 28143635 DOI: 10.3238/arztebl.2017.0011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
476 Pasquinelli F, Belli G, Mazzoni LN, Regini F, Nardi C, Grazioli L, Zignego AL, Colagrande S. MR-diffusion imaging in assessing chronic liver diseases: Does a clinical role exist? Radiol Med. 2012;117:242-253. [PMID: 22020423 DOI: 10.1007/s11547-011-0730-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
477 Lebensztejn DM, Sobaniec-Lotowska ME, Kaczmarski M, Voelker M, Schuppan D. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol 2006; 12(21): 3338-3343 [PMID: 16733849 DOI: 10.3748/wjg.v12.i21.3338] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
478 Rempel JD, Uhanova J. Hepatitis C virus in American Indian/Alaskan Native and Aboriginal peoples of North America. Viruses 2012;4:3912-31. [PMID: 23342378 DOI: 10.3390/v4123912] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
479 Wang H, Mengsteab S, Tag CG, Gao CF, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Transforming growth factor-β1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol 2005; 11(13): 1929-1936 [PMID: 15800982 DOI: 10.3748/wjg.v11.i13.1929] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.4] [Reference Citation Analysis]
480 McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004;53:318-21. [PMID: 14960506 DOI: 10.1136/gut.2003.026393] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 3.5] [Reference Citation Analysis]
481 Navaneethan U, Kemmer N, Neff GW. Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol. 2009;2:287-302. [PMID: 21180557 DOI: 10.1177/1756283X09339079] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
482 Basra S, Anand BS. Definition, epidemiology and magnitude of alcoholic hepatitis. World J Hepatol 2011; 3(5): 108-113 [PMID: 21731902 DOI: 10.4254/wjh.v3.i5.108] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
483 Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Marczyńska M. Is liver biopsy still needed in children with chronic viral hepatitis? World J Gastroenterol 2015; 21(42): 12141-12149 [PMID: 26576098 DOI: 10.3748/wjg.v21.i42.12141] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
484 Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Front Cell Dev Biol 2021;9:730176. [PMID: 34621747 DOI: 10.3389/fcell.2021.730176] [Reference Citation Analysis]
485 Idrees M, Rafique S, Rehman IU, Akbar H, Yousaf MZ, Butt S, Awan Z, Manzoor S, Akram M, Aftab M, Khubaib B, Riazuddin S. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol 2009; 15(40): 5080-5085 [PMID: 19860002 DOI: 10.3748/wjg.15.5080] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
486 Delgado ME, Cárdenas BI, Farran N, Fernandez M. Metabolic Reprogramming of Liver Fibrosis. Cells 2021;10:3604. [PMID: 34944111 DOI: 10.3390/cells10123604] [Reference Citation Analysis]
487 Williamson KD, Gill MG, Andrews JM, Harley HA. Inpatient healthcare utilisation in patients with alcoholic liver disease: what are the costs and outcomes? Intern Med J 2016;46:1407-13. [PMID: 27643595 DOI: 10.1111/imj.13258] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
488 Cho H, Lee HC, Jang SK, Kim YK. Iron increases translation initiation directed by internal ribosome entry site of hepatitis C virus. Virus Genes. 2008;37:154-160. [PMID: 18566883 DOI: 10.1007/s11262-008-0250-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
489 Steindl PE, Ferenci P. CLINICAL ISSUES IN THE MANAGEMENT OF ALCOHOLIC LIVER DISEASE. Clinics in Liver Disease 1998;2:765-79. [DOI: 10.1016/s1089-3261(05)70041-6] [Reference Citation Analysis]
490 Li SM, Li GX, Fu DM, Wang Y, Dang LQ. Liver fibrosis evaluation by ARFI and APRI in chronic hepatitis C. World J Gastroenterol 2014; 20(28): 9528-9533 [PMID: 25071348 DOI: 10.3748/wjg.v20.i28.9528] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
491 Miki D, Aikata H, Uka K, Saneto H, Kawaoka T, Azakami T, Takaki S, Jeong SC, Imamura M, Kawakami Y, Takahashi S, Itamoto T, Asahara T, Arihiro K, Chayama K. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 2008;43:550-557. [PMID: 18648742 DOI: 10.1007/s00535-008-2194-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
492 Larsen FS, Vainer B, Eefsen M, Bjerring PN, Hansen BA. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13(23): 3232-3236 [PMID: 17589903 DOI: 10.3748/wjg.v13.i23.3232] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 71] [Article Influence: 5.3] [Reference Citation Analysis]
493 Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011;12:300-309. [PMID: 21346780 DOI: 10.1038/gene.2011.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
494 Colli A, Colucci A, Paggi S, Fraquelli M, Massironi S, Andreoletti M, Michela V, Conte D. Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. World J Gastroenterol 2005;11:7318-22. [PMID: 16437635 DOI: 10.3748/wjg.v11.i46.7318] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
495 Harris HE, Ramsay ME, Andrews N, Eldridge KP; HCV National Register Steering Group. Hepatitis C virus. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002;324:450-3. [PMID: 11859045 DOI: 10.1136/bmj.324.7335.450] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 3.5] [Reference Citation Analysis]
496 Page A, Mann DA, Mann J. The mechanisms of HSC activation and epigenetic regulation of HSCs phenotypes. Curr Pathobiol Rep 2014;2:163-70. [PMID: 27413631 DOI: 10.1007/s40139-014-0052-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
497 Cheng PN, Chiu YC, Chiu HC, Chien SC. The characteristics of residents with unawareness of hepatitis C virus infection in community. PLoS One 2018;13:e0193251. [PMID: 29470547 DOI: 10.1371/journal.pone.0193251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
498 Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis 2012;55:507-13. [PMID: 22523269 DOI: 10.1093/cid/cis432] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
499 Scheiner B, Mandorfer M, Schwabl P, Payer BA, Bucsics T, Bota S, Aichelburg MC, Grabmeier-Pfistershammer K, Stättermayer A, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. PLoS One 2015;10:e0143429. [PMID: 26599080 DOI: 10.1371/journal.pone.0143429] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
500 Noh R, Lee DH, Kwon BW, Kim YH, Kim SB, Song IH. Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Hepatitis C Virus Infection. Gastroenterol Res Pract. 2016;2016:7476231. [PMID: 27656205 DOI: 10.1155/2016/7476231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
501 Cieśla A, Bociąga-Jasik M, Sobczyk-Krupiarz I, Głowacki MK, Owczarek D, Cibor D, Sanak M, Mach T. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. World J Gastroenterol 2012; 18(35): 4892-4897 [PMID: 23002361 DOI: 10.3748/wjg.v18.i35.4892] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
502 Cooper CL, Badley AD, Angel JB. Characteristics of hepatitis C virus infection in HIV-infected people. Can J Infect Dis 2001;12:157-63. [PMID: 18159334 DOI: 10.1155/2001/542056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
503 Smyth BP, Keenan E, O'Connor JJ. Assessment of hepatitis C infection in injecting drug users attending an addiction treatment clinic. Ir J Med Sci 2000;169:129-32. [PMID: 11006671 DOI: 10.1007/BF03166917] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
504 Zeuzem S. [Chronic hepatitis C : Standard treatment and remaining challenges]. Internist (Berl) 2018;59:528-35. [PMID: 29696303 DOI: 10.1007/s00108-018-0429-y] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
505 Kim SU, Park JY, Kim do Y, Ahn SH, Choi EH, Seok JY, Lee JM, Park YN, Chon CY, Han KH. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int. 2010;4:673-680. [PMID: 21286337 DOI: 10.1007/s12072-010-9201-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
506 Welsch C, Efinger M, von Wagner M, Herrmann E, Zeuzem S, Welzel TM, Lange CM. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response. PLoS One 2017;12:e0171755. [PMID: 28196130 DOI: 10.1371/journal.pone.0171755] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
507 Viganò L, Kluger MD, Laurent A, Tayar C, Merle JC, Lauzet JY, Andreoletti M, Cherqui D. Liver resection in obese patients: results of a case-control study. HPB (Oxford) 2011;13:103-11. [PMID: 21241427 DOI: 10.1111/j.1477-2574.2010.00252.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
508 Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, Daïkha H, Vidaud D, Martinot M, Vidaud M, Degott C, Valla D, Marcellin P. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003;52:1638-43. [PMID: 14570735 DOI: 10.1136/gut.52.11.1638] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 4.4] [Reference Citation Analysis]
509 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.0] [Reference Citation Analysis]
510 Gee I, Alexander G. Liver transplantation for hepatitis C virus related liver disease. Postgrad Med J 2005;81:765-71. [PMID: 16344300 DOI: 10.1136/pgmj.2005.034082] [Reference Citation Analysis]
511 Hu KQ, Yang H, Lin YC, Lindsay KL, Redeker AG. Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. Int J Med Sci 2004;1:92-100. [PMID: 15912201 DOI: 10.7150/ijms.1.92] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
512 Hu G, Liang W, Wu M, Chan Q, Li Y, Xu J, Luo L, Quan X. Staging of rat liver fibrosis using monoexponential, stretched exponential and diffusion kurtosis models with diffusion weighted imaging- magnetic resonance. Oncotarget 2018;9:2357-66. [PMID: 29416777 DOI: 10.18632/oncotarget.23413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
513 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
514 Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24:1073274817729245. [PMID: 28975830 DOI: 10.1177/1073274817729245] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 38.8] [Reference Citation Analysis]
515 Sagnelli C, Martini S, Pisaturo M, Pasquale G, Macera M, Zampino R, Coppola N, Sagnelli E. Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. World J Hepatol 2015; 7(24): 2510-2521 [PMID: 26523204 DOI: 10.4254/wjh.v7.i24.2510] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
516 Ramos CA, Saliba RM, de Pádua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica. 2009;94:249-257. [PMID: 19144658 DOI: 10.3324/haematol.13756] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
517 Brettle RP. Hepatitis C: universal or selective screening? Sex Transm Infect 1998;74:374-5. [PMID: 10195036 DOI: 10.1136/sti.74.5.374] [Reference Citation Analysis]
518 Russmann S, Dowlatshahi EA, Printzen G, Habicht S, Reichen J, Zimmermann H. Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. BMC Gastroenterol. 2007;7:5. [PMID: 17280611 DOI: 10.1186/1471-230x-7-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
519 Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA, Lloyd AR, Jaworowski A, French MA, Lewin SR. HIV and co-infections. Immunol Rev 2013;254:114-42. [PMID: 23772618 DOI: 10.1111/imr.12063] [Cited by in Crossref: 75] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
520 Palmer BA, Schmidt-Martin D, Dimitrova Z, Skums P, Crosbie O, Kenny-Walsh E, Fanning LJ. Network Analysis of the Chronic Hepatitis C Virome Defines Hypervariable Region 1 Evolutionary Phenotypes in the Context of Humoral Immune Responses. J Virol 2015;90:3318-29. [PMID: 26719263 DOI: 10.1128/JVI.02995-15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
521 Fu K, Wang C, Ma C, Zhou H, Li Y. The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Front Pharmacol 2021;12:771459. [PMID: 34803712 DOI: 10.3389/fphar.2021.771459] [Reference Citation Analysis]
522 Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, Akiyama MJ, Norton BL, Litwin AH, Linas BP. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clin Infect Dis 2020;70:1397-405. [PMID: 31095683 DOI: 10.1093/cid/ciz384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
523 Paris AJ, Snapir Z, Christopherson CD, Kwok SY, Lee UE, Ghiassi-Nejad Z, Kocabayoglu P, Sninsky JJ, Llovet JM, Kahana C, Friedman SL. A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. Hepatology 2011;54:2198-207. [PMID: 21837750 DOI: 10.1002/hep.24608] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
524 Nardacci R, Lo Iacono O, Ciccosanti F, Falasca L, Addesso M, Amendola A, Antonucci G, Craxì A, Fimia GM, Iadevaia V. Transglutaminase type II plays a protective role in hepatic injury. Am J Pathol. 2003;162:1293-1303. [PMID: 12651621 DOI: 10.1016/s0002-9440(10)63925-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
525 Fan JH, Xiang MQ, Li QL, Shi HT, Guo JJ. PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis. Gut Liver 2016;10:456-63. [PMID: 26419236 DOI: 10.5009/gnl15261] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
526 El-Hawary MA, El-Raziky MS, Esmat G, Soliman H, Abouzied A, El-Raziky M, El-Akel W, El-Sayed R, Shebl F, Shaheen AA, El-Karaksy H. Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol 2007; 13(20): 2846-2851 [PMID: 17569121 DOI: 10.3748/wjg.v13.i20.2846] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
527 Hall RA, Liebe R, Hochrath K, Kazakov A, Alberts R, Laufs U, Böhm M, Fischer HP, Williams RW, Schughart K, Weber SN, Lammert F. Systems genetics of liver fibrosis: identification of fibrogenic and expression quantitative trait loci in the BXD murine reference population. PLoS One 2014;9:e89279. [PMID: 24586654 DOI: 10.1371/journal.pone.0089279] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
528 Castéra L, Pedeboscq A, Rocha M, Bail BL, Asencio C, Lédinghen V, Bernard PH, Laurent C, Lafon ME, Capdepont M, Couzigou P, Bioulac-Sage P, Balabaud C, Mégraud F, Ménard A. Relationship between the severity of hepatitis C virus-related liver disease and the presence of Helicobacter species in the liver: A prospective study. World J Gastroenterol 2006; 12(45): 7278-7284 [PMID: 17143941 DOI: 10.3748/wjg.v12.i45.7278] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
529 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1016/s0140-6736(08)60383-9] [Cited by in Crossref: 1212] [Cited by in F6Publishing: 538] [Article Influence: 86.6] [Reference Citation Analysis]
530 Tarantino G, Gentile A, Capone D, Basile V, Tarantino M, Minno MNDD, Cuocolo A, Conca P. Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression? World J Gastroenterol 2007; 13(36): 4903-4908 [PMID: 17828823 DOI: 10.3748/wjg.v13.i36.4903] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
531 Sugawara Y, Tamura S, Kokudo N. Antiviral treatment for hepatitis C virus infection after liver transplantation. Hepat Res Treat 2010;2010:475746. [PMID: 21151523 DOI: 10.1155/2010/475746] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
532 Ireland G, Mandal S, Hickman M, Ramsay M, Harris R, Simmons R. Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016. Euro Surveill 2019;24. [PMID: 31362807 DOI: 10.2807/1560-7917.ES.2019.24.30.1800695] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
533 Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, Wiselka M, Norris S. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52:1035-40. [PMID: 12801963 DOI: 10.1136/gut.52.7.1035] [Cited by in Crossref: 180] [Cited by in F6Publishing: 170] [Article Influence: 9.5] [Reference Citation Analysis]
534 Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124-1135. [PMID: 25687730 DOI: 10.1016/s0140-6736(14)62401-6] [Cited by in Crossref: 335] [Cited by in F6Publishing: 143] [Article Influence: 47.9] [Reference Citation Analysis]
535 Huang RH, Hu KQ. A practical approach to managing patients with HCV infection. Int J Med Sci 2006;3:63-8. [PMID: 16614745 DOI: 10.7150/ijms.3.63] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
536 Castéra L, Hézode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, Dhumeaux D. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003;52:288-92. [PMID: 12524415 DOI: 10.1136/gut.52.2.288] [Cited by in Crossref: 217] [Cited by in F6Publishing: 200] [Article Influence: 11.4] [Reference Citation Analysis]
537 Pho MT, Jensen DM, Meltzer DO, Kim AY, Linas BP. Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. J Viral Hepat 2015;22:630-8. [PMID: 26135026 DOI: 10.1111/jvh.12412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
538 Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Hasegawa S, Oketani M, Ido A, Kusumoto K, Hasuike S, Nagata K, Kohara M, Tsubouchi H. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 2009;50:393-9. [PMID: 19585614 DOI: 10.1002/hep.23002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
539 Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology. 2010;51:1445-1449. [PMID: 20077563 DOI: 10.1002/hep.23478] [Cited by in Crossref: 319] [Cited by in F6Publishing: 291] [Article Influence: 26.6] [Reference Citation Analysis]
540 Blixen CE, Webster NJ, Hund AJ, Perzynski AT, Kanuch SW, Stoller EP, McCormick RA, Dawson NV. Communicating about alcohol consumption to nonharmful drinkers with Hepatitis C: patient and provider perspectives. J Gen Intern Med 2008;23:1290-5. [PMID: 22135843 DOI: 10.1007/s11606-008-0649-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
541 Huang CI, Huang CF, Yeh ML, Lin YH, Liang PC, Liu SV, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY, Yu ML. Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes. Medicine (Baltimore) 2018;97:e9782. [PMID: 29517696 DOI: 10.1097/MD.0000000000009782] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
542 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 7.3] [Reference Citation Analysis]
543 Eyawo O, McGinnis KA, Justice AC, Fiellin DA, Hahn JA, Williams EC, Gordon AJ, Marshall BDL, Kraemer KL, Crystal S, Gaither JR, Edelman EJ, Bryant KJ, Tate JP; VACS Project team. Alcohol and Mortality: Combining Self-Reported (AUDIT-C) and Biomarker Detected (PEth) Alcohol Measures Among HIV Infected and Uninfected. J Acquir Immune Defic Syndr 2018;77:135-43. [PMID: 29112041 DOI: 10.1097/QAI.0000000000001588] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
544 Schwimmer JB, Newton KP, Awai HI, Choi LJ, Garcia MA, Ellis LL, Vanderwall K, Fontanesi J. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;38:1267-77. [PMID: 24117728 DOI: 10.1111/apt.12518] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 10.7] [Reference Citation Analysis]
545 Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, Barry MA, Regis C, Kim AY, Marshall A, Saxena S, Smith PC, Linas BP. Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. Clin Infect Dis. 2018;66:376-384. [PMID: 29020317 DOI: 10.1093/cid/cix798] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 14.7] [Reference Citation Analysis]
546 Yoon EJ, Hu KQ. Hepatitis C virus (HCV) infection and hepatic steatosis. Int J Med Sci 2006;3:53-6. [PMID: 16614743 DOI: 10.7150/ijms.3.53] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
547 Barocas JA, So-Armah K, Cheng DM, Lioznov D, Baum M, Gallagher K, Fuster D, Gnatienko N, Krupitsky E, Freiberg MS, Samet JH. Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naïve persons with alcohol use in Russia. PLoS One 2019;14:e0218852. [PMID: 31246992 DOI: 10.1371/journal.pone.0218852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
548 Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Vlahov D, Thomas DL. Changes in blood-borne infection risk among injection drug users. J Infect Dis. 2011;203:587-594. [PMID: 21282191 DOI: 10.1093/infdis/jiq112] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 8.5] [Reference Citation Analysis]
549 Xu HQ, Wang CG, Zhou Q, Gao YH. Effects of alcohol consumption on viral hepatitis B and C. World J Clin Cases 2021; 9(33): 10052-10063 [PMID: 34904075 DOI: 10.12998/wjcc.v9.i33.10052] [Reference Citation Analysis]
550 Sagnelli E, Stroffolini T, Sagnelli C, Pirisi M, Babudieri S, Colloredo G, Russello M, Coppola N, Gaeta GB, Cacopardo B, De Luca M, Almasio PL; EPACRON study group. Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy. Infection 2018;46:93-101. [PMID: 29150796 DOI: 10.1007/s15010-017-1101-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
551 Rosenberg W. Mechanisms of immune escape in viral hepatitis. Gut. 1999;44:759-764. [PMID: 10205220 DOI: 10.1136/gut.44.5.759] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
552 Vlachakis D, Koumandou VL, Kossida S. A holistic evolutionary and structural study of flaviviridae provides insights into the function and inhibition of HCV helicase. PeerJ 2013;1:e74. [PMID: 23678398 DOI: 10.7717/peerj.74] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
553 Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, Wright M, Goldin R, Hill AV, Thomas HC, Thursz MR. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics. 2003;55:362-369. [PMID: 12942209 DOI: 10.1007/s00251-003-0594-5] [Cited by in Crossref: 116] [Cited by in F6Publishing: 109] [Article Influence: 6.1] [Reference Citation Analysis]
554 Maor Y, Malnick SD, Melzer E, Leshno M. Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis. PLoS One 2016;11:e0157832. [PMID: 27410963 DOI: 10.1371/journal.pone.0157832] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
555 Lin AW, Gonzalez SA, Cunningham-Rundles S, Dorante G, Marshall S, Tignor A, Ha C, Jacobson IM, Talal AH. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. Clin Exp Immunol. 2004;137:408-416. [PMID: 15270860 DOI: 10.1111/j.1365-2249.2004.02523.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
556 Szabó E, Lotz G, Páska C, Kiss A, Schaff Z. Viral hepatitis: new data on hepatitis C infection. Pathol Oncol Res. 2003;9:215-221. [PMID: 14688826 DOI: 10.1007/bf02893380] [Cited by in Crossref: 65] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
557 Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: A frequently underestimated combination. World J Gastroenterol 2009; 15(28): 3462-3471 [PMID: 19630099 DOI: 10.3748/wjg.15.3462] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
558 McCartney EM, Beard MR. Impact of alcohol on hepatitis C virus replication and interferon signaling. World J Gastroenterol 2010; 16(11): 1337-1343 [PMID: 20238400 DOI: 10.3748/wjg.v16.i11.1337] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
559 Arias-Loste MT, Cabezas J, Llerena S, Iruzubieta P, San-Segundo D, Merino D, Cuadrado A, Vaqué JP, López-Hoyos M, Crespo J. Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFNγ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells. Viruses 2021;13:635. [PMID: 33917265 DOI: 10.3390/v13040635] [Reference Citation Analysis]
560 Sadeghi F, Salehi-Vaziri M, Almasi-Hashiani A, Gholami-Fesharaki M, Pakzad R, Alavian SM. Prevalence of Hepatitis C Virus Genotypes Among Patients in Countries of the Eastern Mediterranean Regional Office of WHO (EMRO): A Systematic Review and Meta-Analysis. Hepat Mon. 2016;16:e35558. [PMID: 27274353 DOI: 10.5812/hepatmon.35558] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
561 Terrault NA, Im K, Boylan R, Bacchetti P, Kleiner DE, Fontana RJ, Hoofnagle JH, Belle SH. Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol. 2008;6:1403-1411. [PMID: 19081528 DOI: 10.1016/j.cgh.2008.08.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
562 Chekuri S, Nickerson J, Bichoupan K, Sefcik R, Doobay K, Chang S, DelBello D, Harty A, Dieterich DT, Perumalswami PV, Branch AD. Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus. PLoS One 2016;11:e0159413. [PMID: 27442255 DOI: 10.1371/journal.pone.0159413] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
563 Tazawa J, Maeda M, Nakagawa M, Ohbayashi H, Kusano F, Yamane M, Sakai Y, Suzuki K. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci. 2002;47:710-715. [PMID: 11991597 DOI: 10.1023/a:1014715327729] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
564 Zaily DG, Marlen CF, Santiago DC, Gillian MD, Carmen VS, Zurina CE, Enrique R AS, Liz AL, Lisset GF, Sacha LDV, Elena FB. Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. Curr Ther Res Clin Exp 2017;85:20-8. [PMID: 29158855 DOI: 10.1016/j.curtheres.2017.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
565 Eguchi Y, Mizuta T, Yasutake T, Hisatomi A, Iwakiri R, Ozaki I, Fujimoto K. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006; 12(4): 556-560 [PMID: 16489668 DOI: 10.3748/wjg.v12.i4.556] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
566 Maurer CA, Walensi M, Käser SA, Künzli BM, Lötscher R, Zuse A. Liver resections can be performed safely without Pringle maneuver: A prospective study. World J Hepatol 2016; 8(24): 1038-1046 [PMID: 27648156 DOI: 10.4254/wjh.v8.i24.1038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
567 Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113:175-194. [PMID: 29336434 DOI: 10.1038/ajg.2017.469] [Cited by in Crossref: 205] [Cited by in F6Publishing: 176] [Article Influence: 51.3] [Reference Citation Analysis]
568 Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci. 2014;15:10578-10604. [PMID: 24927147 DOI: 10.3390/ijms150610578] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
569 Manousou P, Cholongitas E, Samonakis D, Tsochatzis E, Corbani A, Dhillon AP, Davidson J, Rodríguez-Perálvarez M, Patch D, O’Beirne J. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut. 2014;63:1005-1013. [PMID: 24131637 DOI: 10.1136/gutjnl-2013-305606] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
570 Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: A current molecular and clinical perspective. Liver Res. 2018;2:161-172. [PMID: 31214376 DOI: 10.1016/j.livres.2018.11.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
571 Krajden M, Shivji R, Gunadasa K, Mak A, McNabb G, Friesenhahn M, Hendricks D, Comanor L. Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. J Clin Microbiol 2004;42:4054-9. [PMID: 15364989 DOI: 10.1128/JCM.42.9.4054-4059.2004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
572 Zeybel M, Hardy T, Wong YK, Mathers JC, Fox CR, Gackowska A, Oakley F, Burt AD, Wilson CL, Anstee QM, Barter MJ, Masson S, Elsharkawy AM, Mann DA, Mann J. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med 2012;18:1369-77. [PMID: 22941276 DOI: 10.1038/nm.2893] [Cited by in Crossref: 194] [Cited by in F6Publishing: 176] [Article Influence: 19.4] [Reference Citation Analysis]
573 Lo Re V 3rd, Kostman JR. Management of chronic hepatitis C. Postgrad Med J 2005;81:376-82. [PMID: 15937203 DOI: 10.1136/pgmj.2004.025403] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
574 Leggio L, Ferrulli A, Zambon A, Caputo F, Kenna GA, Swift RM, Addolorato G. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav 2012;37:561-4. [PMID: 22244707 DOI: 10.1016/j.addbeh.2011.12.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
575 Qu J, Yu Z, Li Q, Chen Y, Xiang D, Tan L, Lei C, Bai W, Li H, Shang Q, Chen L, Hu X, Lu W, Li Z, Chen D, Wang X, Zhang C, Xiao G, Qi X, Chen J, Zhou L, Chen G, Li Y, Zeng Z, Rong G, Dong Z, Chen Y, Lou M, Wang C, Lu Y, Zhang C, Yang Y. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. Trials. 2014;15:438. [PMID: 25381721 DOI: 10.1186/1745-6215-15-438] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
576 Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, Hashimoto S, Sasaki R, Bekki S, Kugiyama Y, Miyazoe Y, Kuno A, Korenaga M, Togayachi A, Ocho M, Mizokami M, Narimatsu H, Yatsuhashi H. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014;60:1563-1570. [PMID: 25042054 DOI: 10.1002/hep.27305] [Cited by in Crossref: 153] [Cited by in F6Publishing: 144] [Article Influence: 19.1] [Reference Citation Analysis]
577 Zhu S, Wu L, Mei Y, Liu Z, Lin L, Yuan J, Li J, Li X, Peng L. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol. BMJ Open 2021;11:e049104. [PMID: 34697111 DOI: 10.1136/bmjopen-2021-049104] [Reference Citation Analysis]
578 Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. [PMID: 19330875 DOI: 10.1002/hep.22759] [Cited by in Crossref: 2134] [Cited by in F6Publishing: 1938] [Article Influence: 164.2] [Reference Citation Analysis]
579 Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation. SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol 2012;18 Suppl:S1-32. [PMID: 23006491 DOI: 10.4103/1319-3767.101155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
580 Meijer K, Smid WM, Van Der Meer J. Treatment of chronic hepatitis C in haemophilia patients: TREATMENT OF CHRONIC HEPATITIS C IN HAEMOPHILIA PATIENTS. Haemophilia 2000;6:605-13. [DOI: 10.1046/j.1365-2516.2000.00398.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
581 Zignego AL, Giannini C, Gragnani L, Piluso A, Fognani E. Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. J Transl Med. 2012;10:158. [PMID: 22863056 DOI: 10.1186/1479-5876-10-158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
582 Wyatt J, Baker H, Prasad P, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol. 2004;5:402-406. [PMID: 15047745 DOI: 10.1136/jcp.2003.009357] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
583 Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013;19:5219-5238. [PMID: 23394097 DOI: 10.2174/13816128113199990381] [Cited by in Crossref: 128] [Cited by in F6Publishing: 113] [Article Influence: 16.0] [Reference Citation Analysis]
584 Jafferbhoy H, Gashau W, Dillon J. Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. Clinicoecon Outcomes Res 2010;2:87-96. [PMID: 21935317 DOI: 10.2147/ceor.s7283] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
585 McCartney EM, Beard MR. Impact of alcohol on hepatitis C virus replication and interferon signaling. World J Gastroenterol. 2010;16:1337-1343. [PMID: 20238400 DOI: 10.3748/wjg.16.1337] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
586 Nakaoka K, Hashimoto S, Kawabe N, Nitta Y, Murao M, Nakano T, Shimazaki H, Kan T, Takagawa Y, Ohki M. PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients. Springerplus. 2015;4:83. [PMID: 25713769 DOI: 10.1186/s40064-015-0870-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
587 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms20061358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 19.7] [Reference Citation Analysis]
588 Racanelli V, Frassanito MA, Leone P, Galiano M, De Re V, Silvestris F, Dammacco F. Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules. J Virol. 2006;80:3923-3934. [PMID: 16571809 DOI: 10.1128/jvi.80.8.3923-3934.2006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
589 Li PY, Zhou XJ, Yao L, Fang XH, Ren JN, Song JW. Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes. World J Gastroenterol 2012; 18(44): 6481-6488 [PMID: 23197895 DOI: 10.3748/wjg.v18.i44.6481] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
590 Mehta SH, Sudarshi D, Srikrishnan AK, Celentano DD, Vasudevan CK, Anand S, Kumar MS, Latkin C, Solomon S, Solomon SS. Factors associated with injection cessation, relapse and initiation in a community-based cohort of injection drug users in Chennai, India. Addiction 2012;107:349-58. [PMID: 21815960 DOI: 10.1111/j.1360-0443.2011.03602.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
591 Karoney MJ, Siika AM. Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J 2013;14:44. [PMID: 23560127 DOI: 10.11604/pamj.2013.14.44.2199] [Cited by in Crossref: 23] [Cited by in F6Publishing: 55] [Article Influence: 2.6] [Reference Citation Analysis]
592 Livingston SE, Deubner H, Bruden DL, McMahon BJ, Homan CE, Townshend-Bulson LJ, Bruce MG, Hennessy TW, Williams JL, Gretch DR. Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C. Can J Gastroenterol 2010;24:445-51. [PMID: 20652161 DOI: 10.1155/2010/692036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
593 Kuniholm MH, Gao X, Xue X, Kovacs A, Marti D, Thio CL, Peters MG, Greenblatt RM, Goedert JJ, Cohen MH, Minkoff H, Gange SJ, Anastos K, Fazzari M, Young MA, Strickler HD, Carrington M. The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women. J Infect Dis 2011;203:1807-14. [PMID: 21606539 DOI: 10.1093/infdis/jir192] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
594 Gordon SC, Lamerato LE, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale E, Xu F, Boscarino JA, Vijayadeva V, Schmidt MA, Oja-Tebbe N, Lu M. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol 2015;110:1169-77; quiz 1178. [PMID: 26215529 DOI: 10.1038/ajg.2015.203] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
595 Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009;54:1317-1324. [PMID: 18958621 DOI: 10.1007/s10620-008-0500-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 5.2] [Reference Citation Analysis]
596 Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263-270. [PMID: 22056542 DOI: 10.7326/0003-4819-156-4-201202210-00378] [Cited by in Crossref: 221] [Cited by in F6Publishing: 219] [Article Influence: 20.1] [Reference Citation Analysis]
597 Raizner A, Shillingford N, Mitchell PD, Harney S, Raza R, Serino J, Jonas MM, Lee CK. Hepatic Inflammation May Influence Liver Stiffness Measurements by Transient Elastography in Children and Young Adults. J Pediatr Gastroenterol Nutr. 2017;64:512-517. [PMID: 27540711 DOI: 10.1097/mpg.0000000000001376] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
598 Rodríguez-Castro KI, De Martin E, Gambato M, Lazzaro S, Villa E, Burra P. Female gender in the setting of liver transplantation. World J Transplant 2014; 4(4): 229-242 [PMID: 25540733 DOI: 10.5500/wjt.v4.i4.229] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
599 Neal KR, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut. 2007;56:1098-1104. [PMID: 17344277 DOI: 10.1136/gut.2006.113217] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 4.7] [Reference Citation Analysis]
600 Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006;55:1650-60. [PMID: 17047111 DOI: 10.1136/gut.2006.091454] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 5.6] [Reference Citation Analysis]
601 Vairetti M, Di Pasqua LG, Cagna M, Richelmi P, Ferrigno A, Berardo C. Changes in Glutathione Content in Liver Diseases: An Update. Antioxidants (Basel) 2021;10:364. [PMID: 33670839 DOI: 10.3390/antiox10030364] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
602 Kappel CR, Kretzmann NA, Alvares-da-Silva MR. IRS1 Expression in Hepatic Tissue and Leukocytes in Chronic Hepatitis C Virus Infected Patients: A Comparative Study. Int J Hepatol 2012;2012:698905. [PMID: 22830036 DOI: 10.1155/2012/698905] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
603 Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol 2020; 26(22): 2931-2947 [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]